Alliance HealthCare Services (AIQ) 10-Q 9 May 17 2017 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2017	Apr. 28, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Trading Symbol	AIQ
Entity Registrant Name	Alliance HealthCare Services, Inc
Entity Central Index Key	817,135
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		10,831,300

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 21,472	$ 22,241
Accounts receivable, net of allowance for doubtful accounts of $3,946 in 2017 and $4,008 in 2016	74,694	77,496
Prepaid expenses	8,428	9,568
Other current assets	3,917	3,853
Total current assets	108,511	113,158
Plant, property and equipment, net	194,334	204,814
Goodwill	119,130	119,130
Other intangible assets, net	195,699	198,977
Other assets	27,968	23,785
Total assets	645,642	659,864
Current liabilities:
Accounts payable	27,071	28,185
Accrued compensation and related expenses	19,026	24,895
Accrued interest payable	3,205	3,308
Current portion of long-term debt	19,519	17,298
Current portion of obligations under capital leases	3,397	3,354
Other accrued liabilities	27,656	29,323
Total current liabilities	99,874	106,363
Long-term debt, net of current portion	508,513	515,407
Obligations under capital leases, net of current portion	11,820	12,686
Deferred income taxes	25,732	25,818
Other liabilities	9,646	9,093
Total liabilities	655,585	669,367
Commitments and contingencies (Note 12)
Stockholders’ deficit:
Preferred stock, $0.01 par value; 1,000,000 shares authorized and no shares issued and outstanding	0	0
Common stock, $0.01 par value; 100,000,000 shares authorized; 10,989,273 and 10,970,937 issued in 2017 and 2016, respectively; 10,831,300 and 10,812,964 outstanding in 2017 and 2016, respectively	110	110
Treasury stock, at cost - 157,973 shares in 2017 and 2016	(3,138)	(3,138)
Additional paid-in capital	61,734	61,353
Accumulated comprehensive income	42	10
Accumulated deficit	(198,514)	(197,900)
Total stockholders’ deficit attributable to Alliance HealthCare Services, Inc.	(139,766)	(139,565)
Noncontrolling interest	129,823	130,062
Total stockholders’ deficit	(9,943)	(9,503)
Total liabilities and stockholders’ deficit	$ 645,642	$ 659,864

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Allowance for doubtful accounts	$ 3,946	$ 4,008
Preferred stock, par value (dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	10,989,273	10,970,937
Common stock, shares outstanding	10,831,300	10,812,964
Treasury stock, shares	157,973	157,973

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Income Statement [Abstract]
Revenues	$ 129,936	$ 123,725
Costs and expenses:
Cost of revenues, excluding depreciation and amortization	75,049	70,914
Selling, general and administrative expenses	23,535	25,265
Transaction costs	162	417
Shareholder transaction costs	869	1,009
Severance and related costs	634	1,716
Depreciation expense	14,073	13,048
Amortization expense	3,275	2,443
Interest expense, net	8,700	7,495
Other income, net	(483)	(787)
Total costs and expenses	125,814	121,520
Income before income taxes, earnings from unconsolidated investees, and noncontrolling interest	4,122	2,205
Income tax benefit	(3)	(945)
Earnings from unconsolidated investees	(336)	(252)
Net income	4,461	3,402
Less: Net income attributable to noncontrolling interest	(5,075)	(4,592)
Net loss attributable to Alliance HealthCare Services, Inc.	(614)	(1,190)
Comprehensive loss, net of taxes:
Net income	4,461	3,402
Unrealized gain (loss) on hedging transactions, net of taxes of $0 and $0	13	(38)
Reclassification adjustment for losses realized and included in net loss, net of taxes of $0 and $0	19
Total comprehensive income, net of taxes	4,493	3,364
Comprehensive income attributable to noncontrolling interest	(5,075)	(4,592)
Comprehensive loss attributable to Alliance HealthCare Services, Inc.	$ (582)	$ (1,228)
Loss per common share attributable to Alliance HealthCare Services, Inc.:
Basic	$ (0.06)	$ (0.11)
Diluted	$ (0.06)	$ (0.11)
Weighted average number of shares of common stock and common stock equivalents:
Basic	10,973	10,779
Diluted	10,973	10,779

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Income Statement [Abstract]
Unrealized gain (loss) on hedging transactions, tax	$ 0	$ 0
Reclassification adjustment for losses realized and included in net loss, tax	$ 0	$ 0

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Operating activities:
Net income	$ 4,461	$ 3,402
Adjustments to reconcile net income to net cash provided by operating activities:
Provision for doubtful accounts	502	270
Share-based payment	381	1,402
Depreciation and amortization	17,348	15,491
Amortization of deferred financing costs	2,455	960
Accretion of discount on long-term debt	131	126
Adjustment of derivatives to fair value	(7)	(114)
Distributions from unconsolidated investees	143	217
Earnings from unconsolidated investees	(336)	(252)
Deferred income taxes	(86)	(1,438)
Gain on sale of assets, net	(482)	(296)
Excess tax benefit from share-based payment arrangements	0	436
Changes in operating assets and liabilities, net of the effects of acquisitions:
Accounts receivable	2,300	1,020
Prepaid expenses	1,147	1,102
Other current assets	(93)	230
Other assets	105	160
Accounts payable	(1,538)	(4,493)
Accrued compensation and related expenses	(5,869)	505
Accrued interest payable	(103)	(11)
Income taxes payable	24	(14)
Other accrued liabilities	(609)	4,003
Net cash provided by operating activities	19,874	22,706
Investing activities:
Equipment purchases	(839)	(17,675)
Increase in deposits on equipment	(6,432)	(4,489)
Acquisitions, net of cash received	(524)	(1,018)
Proceeds from sale of assets	571	830
Net cash used in investing activities	(7,224)	(22,352)
Financing activities:
Principal payments on equipment debt and capital lease obligations	(4,101)	(3,956)
Proceeds from equipment debt	2,539	962
Principal payments on term loan facility	(1,300)	(1,300)
Principal payments on revolving loan facility	(9,000)	(6,000)
Proceeds from revolving loan facility	4,000	15,000
Payments of debt issuance costs and deferred financing costs	(223)	(24,969)
Distributions to noncontrolling interest in subsidiaries	(5,600)	(4,149)
Contributions from noncontrolling interest in subsidiaries	286	0
Excess tax benefit from share-based payment arrangements	0	(436)
Issuance of common stock	0	1
Proceeds from exercise of stock options	0	485
Settlement of contingent consideration related to acquisitions	(20)	0
Proceeds from shareholder transaction	0	28,629
Net cash (used in) provided by financing activities	(13,419)	4,267
Net (decrease) increase in cash and cash equivalents	(769)	4,621
Cash and cash equivalents, beginning of period	22,241	38,070
Cash and cash equivalents, end of period	21,472	42,691
Supplemental disclosure of cash flow information:
Interest paid	6,286	6,448
Income taxes paid (refunded), net	9	(73)
Supplemental disclosure of non-cash investing and financing activities:
Changes in equipment purchases in accounts payable and accrued equipment	22	3,521
Noncontrolling interest assumed in connection with acquisitions	$ 0	$ 1,716

Basis of Presentation, Principl

Basis of Presentation, Principles of Consolidation, and Use of Estimates	3 Months Ended
	Mar. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation, Principles of Consolidation, and Use of Estimates	1. Basis of Presentation, Principles of Consolidation, and Use of Estimates Basis of Presentation The accompanying condensed consolidated financial statements have been prepared by Alliance HealthCare Services, Inc. (the “Company” or “Alliance”) in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. The accompanying condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes to the consolidated financial statements for the year ended December 31, 2016. For a complete summary Pending Transaction On April 10, 2017, the Company entered into an agreement and plan of merger (the “Merger Agreement”) by and among Tahoe Investment Group Co., Ltd., an entity organized under the laws of the People’s Republic of China (“Tahoe”), THAIHOT Investment Company Limited, an exempted company incorporated under the laws of the Cayman Islands and indirect wholly-owned subsidiary of Tahoe (“THAIHOT”), THAIHOT Investment Company US Limited, a Delaware corporation and indirect wholly-owned subsidiary of Tahoe (“Parent”) and Alliance Healthcare Services Merger Sub Limited, a Delaware corporation and wholly-owned subsidiary of Parent (“Sub” and together with Tahoe, THAIHOT and Parent, the “Purchaser Parties”) providing for the merger of Sub with and into Alliance (the “Merger”), with Alliance surviving the Merger as a wholly-owned subsidiary of Parent. Under the Merger Agreement, the Purchaser Parties will acquire all of the Company’s outstanding common stock that is not beneficially owned by the Purchaser Parties or owned by the Company as treasury shares. The Merger is subject to approval by Alliance’s stockholders, including a non-waiveable condition requiring approval by the holders of a majority of the outstanding shares of Alliance common stock that are not beneficially owned by the Purchaser Parties or certain senior executive officers of the Company, as well as certain other customary closing conditions. The Merger is not subject to a financing condition. The Company will call a meeting of stockholders for the purpose of voting on the adoption of the Merger Agreement in due course. If completed, the Merger will result in the Company becoming a privately held company and Alliance’s common stock would no longer be listed on NASDAQ. See Note 17 for details. Principles of Consolidation The accompanying condensed consolidated financial statements of the Company include the assets, liabilities, revenues and expenses of all subsidiaries over which the Company exercises control. Intercompany transactions have been eliminated. The Company evaluates participating rights in its assessment of control in determining consolidation of joint venture partners. The Company records noncontrolling interest related to its consolidated subsidiaries that are not wholly-owned. Investments in unconsolidated investees over which it exercises significant influence but does not control are accounted for under the equity method. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2017
New Accounting Pronouncements And Changes In Accounting Principles [Abstract]
Recent Accounting Pronouncements	2. Recent Accounting Pronouncements Revenue Recognition In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606),” to clarify and converge the revenue recognition principles under GAAP and International Financial Reporting Standards and to develop guidance that would streamline and enhance revenue recognition requirements while also providing a more robust framework for addressing revenue issues. ASU 2014-09 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry specific guidance. Key provisions of the ASU involve a 5-step model specific to recognizing revenue derived from customer contracts. In addition, ASU 2014-09 provides implementation guidance on several other important topics, including the accounting for certain revenue-related costs. The Company will be required to capitalize costs to acquire new contracts, whereas currently, the Company expenses those costs as incurred. In August 2015, the FASB issued an amendment to provide a one-year deferral of the effective date to annual reporting periods beginning on or after December 15, 2017 for publicly traded business entities. Early adoption of the standard as of December 15, 2016 (for interim and annual reporting periods beginning after that date) is permitted. The Company is currently working through an adoption plan, including identifying its revenue streams and completing a preliminary analysis of how it currently accounts for revenue transactions compared to the revenue accounting required under the new standard. The Company intends to complete its adoption plan in 2017. This plan includes a review of transactions supporting each revenue stream to determine the impact of accounting treatment under Accounting Standards Codification (“ASC”) 606, “Revenue from Contracts with Customers,” and the completion of a rollout plan for implementation of the new standard with affected functions in its organization. Because of the nature of the work that remains, at this time the Company is unable to reasonably estimate the impact of adoption on its consolidated financial statements. ASU 2014-09 will be effective for the Company beginning on January 1, 2018. Leases In February 2016, the FASB issued ASU 2016-02, “Leases,” to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The ASU supersedes the current guidance. The primary difference between current guidance and ASU 2016-02 is the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP. ASU 2016-02 also requires an entity to separate the lease components from the non-lease components (for example, maintenance services or other activities that transfer a good or service to the customer) in a contract. Only the lease components must be accounted for in accordance with this guidance. ASU 2016-02 is effective for publicly traded business entities for annual reporting periods beginning after December 15, 2018, including interim reporting periods within that reporting period. Early adoption is permitted. ASU 2016-02 will be effective for the Company beginning on January 1, 2019. The Company is assessing the impact, if any, that the adoption of ASU 2016-02 may have on its consolidated financial statements. Share-Based Payments In March 2016, the FASB issued ASU 2016-09, “Compensation – Stock Compensation (Topic 718),” which simplifies several aspects of the accounting for employee share-based payment transactions for both public and nonpublic entities, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. ASU 2016-09 is effective for publicly traded business entities for annual reporting periods beginning after December 15, 2016, including interim periods within those annual reporting periods. The Company adopted ASU 2016-09 on January 1, 2017. As required by the standard, $0.2 million of tax deficiencies recognized on stock-based compensation expense were reflected in the Company’s condensed consolidated statements of operations and comprehensive loss as a component of the benefit for income taxes rather than paid-in capital on a prospective basis during the three months ended March 31, 2017. At January 1, 2017, the Company had no previously unrecognized excess tax benefits, the cumulative effect of which would be required by the standard to be recorded as an adjustment to accumulated deficit. The Company also elected to prospectively apply the change in presentation of excess tax benefits wherein excess tax benefits recognized on stock-based compensation expense were classified as operating activities in our condensed consolidated statements of cash flows for the three months ended March 31, 2017. Presentation requirements for cash flows related to employee taxes paid for withheld shares had no impact to all periods presented as such cash flows have historically been presented as financing activities. Further, the Company did not elect an accounting policy change to record forfeitures as they occur and thus continues to estimate forfeitures at each period. Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments,” which is intended to reduce diversity in the classification of transactions related to debt prepayment or debt extinguishment costs, zero-coupon debt instruments settlement, contingent consideration payments made after a business combination, insurance claims settlement and corporate-owned life insurance settlement, distributions from equity method investments and beneficial interests in securitization transactions. This guidance is effective for publicly traded business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. ASU 2016-15 will be effective for the Company beginning on January 1, 2018. The Company is assessing the impact, if any, that the adoption of ASU 2016-15 may have on its consolidated financial statements . Income Taxes In October 2016, the FASB issued ASU 2016-16, “Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory.” This amendment is intended to improve accounting for the income tax consequences of intra-entity transfers of assets other than inventory. In accordance with this guidance, an entity should recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The ASU will be effective for the Company beginning on January 1, 2018. Early adoption is permitted. The Company is assessing the impact, if any, that the adoption of ASU 2016-16 may have on its consolidated financial statements. Statement of Cash Flows: Restricted Cash In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230): Restricted Cash,” which provides amendments to current guidance to address the classifications and presentation of changes in restricted cash in the statement of cash flows. ASU 2016-18 will be effective for the Company beginning on January 1, 2018. Early adoption is permitted. The Company does not anticipate that the adoption of ASU 2016-18 will have a material impact on its consolidated financial statements. Business Combinations In January 2017, the FASB issued ASU 2017-01, “Business Combinations (Topic 805): Clarifying the Definition of a Business,” which clarifies the definition of a business to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. ASU 2017-01 is effective for fiscal years beginning after December 15, 2017, including interim periods within that year. The amendments in ASU 2017-01 should be applied prospectively on or after the effective date. Early adoption is permitted. ASU 2017-01 will be effective for the Company beginning on January 1, 2018. The Company is assessing the impact, if any, that the adoption of ASU 2017-01 may have on its consolidated financial statements. Accounting Changes and Error Corrections In January 2017, the FASB issued ASU No. 2017-03, “Accounting Changes and Error Corrections (Topic 250) and Investments – Equity Method and Joint Ventures (Topic 323): Amendments to SEC Paragraphs Pursuant to Staff Announcements at the September 22, 2016 and November 17, 2016 EITF Meetings.” The new guidance is intended to provide clarity in relation to the disclosure of the impact that ASU 2014-09 and ASU 2016-02 will have on the Company’s financial statements when adopted. The effective date for this guidance is the same as the effective date for ASU 2014-09 and ASU 2016-02. The Company is currently evaluating the effect that the adoption of ASU 2017-03 will have on its consolidated financial statements. Intangibles – Goodwill and Other In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other (Topic 350) – Simplifying the Test for Goodwill Impairment,” which eliminates the second step from the goodwill impairment test and instead requires an entity to recognize a goodwill impairment charge for the amount by which the goodwill carrying amount exceeds the reporting unit’s fair value. The amendments in ASU 2017-04 are effective for public business entities for annual or interim goodwill impairment tests in annual periods beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company early-adopted ASU 2017-04 on a prospective basis during the three months ended March 31, 2017. The adoption did not have any impact on the Company’s consolidated financial statements.

Transactions

Transactions	3 Months Ended
	Mar. 31, 2017
Business Combinations Restructuring And Related Activities [Abstract]
Transactions	3. Transactions Tahoe Transaction On September 16, 2015, Tahoe agreed to purchase approximately 5,537,945 shares of the Company’s common stock from funds managed by Oaktree Capital Management, L.P. (“Oaktree”) and MTS Health Investors, LLC (“MTS”), and Larry C. Buckelew (together, The Tahoe Transaction closed on March 29, 2016. Tahoe, through a wholly-owned subsidiary, owned an aggregate of approximately 51% of the Company’s outstanding shares of common stock as of March 31, 2017. The Company has not agreed to pay any management fees to Tahoe for any financial advisory services provided to the Company. On April 10, 2017, the Company entered into a Merger Agreement with Tahoe, pursuant to which Tahoe will acquire all of the Company’s outstanding common stock that is not beneficially owned by Tahoe or owned by the Company as treasury shares. See Note 1 and Note 17 for details. Restructuring Plan From time to time, the Company’s management implements individually immaterial restructuring plans, including the closure or consolidation of certain sites as a result of the loss of certain customers. The impact of the charges resulting from restructuring plans are summarized below: Three Months Ended March 31, (in thousands) 2017 2016 Cost of revenues, excluding depreciation and amortization $ 77 $ 200 Selling, general and administrative expenses 19 31 Other expense, net 119 — Total restructuring charges $ 215 $ 231 The restructuring plans, under which costs were incurred during the three months ended March 31, 2017 and 2016, were adopted at varying times, beginning in 2009, and are expected to be completed by the third quarter of 2019.

Share-Based Payment

Share-Based Payment	3 Months Ended
	Mar. 31, 2017
Share Based Compensation [Abstract]
Share-Based Payment	4. Share-Based Payment Stock Option Plans and Awards In November 1999, the Company adopted an employee stock option plan (as amended and restated, the “1999 Equity Plan”) pursuant to which options and awards with respect to a total of 3,005,000 shares have become available for grant. As of March 31, 2017, a total of 975,647 shares remained available for grant under the 1999 Equity Plan. The following weighted average assumptions were used in the estimated grant date fair value calculations for stock option awards: Three Months Ended March 31, 2016 Risk free interest rate 1.53 % Expected dividend yield — % Expected stock price volatility 66.5 % Average expected life (in years) 6.00 Weighted average fair value on grant date $ 7.16 The following table summarizes the Company’s stock option activity: (dollars in thousands, except per share amounts) Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (1) Outstanding at December 31, 2016 650,969 $ 18.51 Canceled/forfeited (26,242 ) 34.23 Outstanding at March 31, 2017 624,727 17.85 6.34 $ 1,119 Vested and expected to vest in the future at March 31, 2017 598,945 18.31 6.22 $ 1,039 Vested and exercisable at March 31, 2017 500,086 20.51 5.68 $ 736 (1) Represents the difference between the exercise price and the value of the Company’s stock at fiscal quarter-end. The following table summarizes the Company’s unvested stock option activity: (dollars in thousands, except per share amounts) Shares Weighted Average Grant-Date Fair Value Aggregate Unrecognized Compensation Weighted Average Period Over Which Expected to be Recognized (in years) Total Fair Value Unvested at December 31, 2016 187,804 $ 4.33 Vested (62,303 ) 4.33 $ 270 Forfeited (860 ) 4.18 Unvested at March 31, 2017 124,641 $ 4.33 $ 421 2.0 Stock Awards The 1999 Equity Plan permits the award of restricted stock, restricted stock units (“RSUs”), stock bonus awards and performance-based stock awards (collectively referred to as “stock awards”). The following table summarizes the Company’s RSU activity: (dollars in thousands, except per share amounts) Shares Weighted Average Grant-Date Fair Value Aggregate Unrecognized Compensation Weighted Average Period Over Which Expected to be Recognized (in years) Unvested at December 31, 2016 167,853 $ 8.37 Vested (25,690 ) 6.93 Forfeited (519 ) 6.93 Unvested at March 31, 2017 141,644 $ 8.63 $ 929 1.1 Share-based Compensation Expense The following table summarizes pre-tax share-based compensation expense included within “Selling, general and administrative expenses” in the condensed consolidated statements of operations and comprehensive loss: Three Months Ended March 31, (in thousands) 2017 2016 Share-based compensation expense $ 381 $ 1,865 (1) (1) Decrease in share-based compensation expense was primarily due to additional expense recognized during the three months ended March 31, 2016 related to a change in control in connection with the Tahoe Transaction in March 2016 (see Note 3). This includes cash paid of $463 related to market performance RSUs, granted to executive management, which vested upon a change in control of the Company under the terms of the RSU award agreement.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	5. Fair Value of Financial Instruments Instruments Measured at Fair Value on a Recurring Basis The following table summarizes the valuation of the Company’s financial instruments that are reported at fair value on a recurring basis: Fair Value as of March 31, 2017 Fair Value as of December 31, 2016 (in thousands) Total Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Financial assets: Interest rate contracts - asset position $ 68 $ — $ 68 $ — $ 55 $ — $ 55 $ — Total financial assets $ 68 $ — $ 68 $ — $ 55 $ — $ 55 $ — Financial liabilities: Contingent consideration related to acquisitions $ 535 $ — $ — $ 535 $ 555 $ — $ — $ 555 Mandatorily redeemable noncontrolling interest 2,386 — — 2,386 2,386 — — 2,386 Interest rate contracts - liability position 26 — 26 — 53 — 53 — Total financial liabilities $ 2,947 $ — $ 26 $ 2,921 $ 2,994 $ — $ 53 $ 2,941 The Company’s derivative instruments are primarily pay-fixed, receive-variable interest rate swaps based on the London interbank offered rate (“LIBOR”) swap rate. The Company has elected to use the income approach to value these derivatives, using observable Level 2 market expectations at measurement date and standard valuation techniques to convert future amounts to a single present amount assuming that participants are motivated, but not compelled to transact. Level 2 inputs for interest rate swap valuations are limited to quoted prices for similar assets or liabilities in active markets (specifically futures contracts on LIBOR for the first two years) and inputs other than quoted prices that are observable for the asset or liability (specifically LIBOR cash and swap rates at commonly quoted intervals and implied volatilities for options). According to ASC 820, “Fair Value Measurement,” the fair value measurement of an asset or liability must reflect the nonperformance risk of the entity and the counterparty. Therefore, the impact of the counterparty’s creditworthiness and the Company’s creditworthiness have also been factored into the fair value measurement of the derivative instruments. For additional information see Note 9. The fair value of the liability for contingent consideration related to acquisitions was estimated using probability-adjusted performance estimates (Level 3 inputs) over the performance periods following the transaction dates. These estimates represent inputs for which market data are not available and are developed using the best information available about the assumptions that market participants would use when pricing the liability. Significant increases or decreases to either of these inputs in isolation would result in a significantly higher or lower liability. Ultimately, the liability will be equivalent to the amount paid, and the difference between the fair value estimate and amount paid will be recorded in earnings. Changes in the fair value of the Company’s Level 3 liabilities for the three months ended March 31, 2017 were as follows: (in thousands) Contingent consideration related to acquisitions Mandatorily redeemable noncontrolling interest Balance at December 31, 2016 $ 555 $ 2,386 Settlement (20 ) — Balance at March 31, 2017 $ 535 $ 2,386 Financial instruments measured and recorded at fair value on a recurring basis were presented on the Company’s consolidated balance sheets as follows: Fair Value as of March 31, 2017 Fair Value as of December 31, 2016 (in thousands) Total Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Financial assets: Other assets $ 68 $ — $ 68 $ — $ 55 $ — $ 55 $ — Total financial assets $ 68 $ — $ 68 $ — $ 55 $ — $ 55 $ — Financial liabilities: Other accrued liabilities $ 2,947 $ — $ 26 $ 2,921 $ 2,994 $ — $ 53 $ 2,941 Total financial liabilities $ 2,947 $ — $ 26 $ 2,921 $ 2,994 $ — $ 53 $ 2,941 During the three months ended March 31, 2017, none of the Company’s financial instruments were transferred from one level to another. Instruments Not Recorded at Fair Value on a Recurring Basis The following table summarizes the fair values and book values of the Company’s long-term debt: March 31, 2017 December 31, 2016 (in thousands) Fair Value Book Value Fair Value Book Value Variable-rate debt $ 526,447 $ 528,879 $ 526,475 $ 533,939 Fixed-rate debt 38,617 36,640 41,572 39,308 $ 565,064 $ 565,519 $ 568,047 $ 573,247 The fair value of long-term debt is estimated using Level 2 inputs based on quoted market prices or pricing models using current market rates. Assets and Liabilities Recorded at Fair Value on a Non-Recurring Basis The Company also measures the fair value of certain assets on a non-recurring basis (utilizing Level 3 inputs), generally on an annual basis, in connection with acquisitions, or when events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. These assets include goodwill, intangible assets, long-lived assets and investments in unconsolidated investees. See Note 6 for a discussion of the Company’s annual impairment test for goodwill and indefinite-lived intangible assets.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
	Mar. 31, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	6. Goodwill and Intangible Assets Changes in the carrying amount of goodwill are as follows: (in thousands) Radiology Oncology Interventional Total Balance at December 31, 2016 $ 45,157 $ 42,320 $ 31,653 $ 119,130 Goodwill acquired during the period — — — — Adjustments to goodwill during the period — — — — Balance at March 31, 2017 $ 45,157 $ 42,320 $ 31,653 $ 119,130 Gross goodwill $ 199,499 $ 62,222 $ 31,653 $ 293,374 Accumulated impairment charges (154,342 ) (19,902 ) — (174,244 ) Balance at March 31, 2017 $ 45,157 $ 42,320 $ 31,653 $ 119,130 Intangible assets consisted of the following: Weighted Average March 31, 2017 December 31, 2016 (dollars in thousands) Useful Life (in years) Gross Carrying Amount Accumulated Amortization Intangible Assets, Net Gross Carrying Amount Accumulated Amortization Intangible Assets, Net Finite-lived intangible assets: Customer contracts 16 $ 230,323 $ (104,179 ) $ 126,144 $ 230,323 $ (101,240 ) $ 129,083 Other 18 41,820 (22,480 ) 19,340 41,820 (22,141 ) 19,679 Total finite-lived intangible assets 16 $ 272,143 $ (126,659 ) $ 145,484 $ 272,143 $ (123,381 ) $ 148,762 Indefinite-lived intangible assets 50,215 50,215 Total other intangible assets $ 195,699 $ 198,977 In 2017, the Company intends to perform its annual impairment test for goodwill and indefinite-lived intangible assets in the fourth quarter, absent other events occurring or changes in circumstances that would more-likely-than-not reduce the fair value of a reporting unit below its carrying amount. Based on financial information as of March 31, 2017, impairment testing was not required during the three months then ended. Amortization expense for finite-lived intangible assets is reported as “Amortization expense” in the consolidated statements of operations and comprehensive loss. As of March 31, 2017, estimated future amortization expense for each of the fiscal years ending December 31, is presented below: (in thousands) Remainder of 2017 $ 9,784 2018 12,689 2019 12,200 2020 11,710 2021 10,802 Thereafter 88,299 $ 145,484

Supplemental Balance Sheet Info

Supplemental Balance Sheet Information	3 Months Ended
	Mar. 31, 2017
Supplemental Balance Sheet Information [Abstract]
Supplemental Balance Sheet Information	7. Supplemental Balance Sheet Information Plant, property and equipment, net as of March 31, 2017 are as follows: Accumulated Net Carrying (in thousands) Cost Depreciation Amount Furniture and fixtures $ 4,835 $ (4,202 ) $ 633 Office equipment 80,284 (58,943 ) 21,341 Transportation and service equipment 15,653 (4,576 ) 11,077 Major equipment 783,155 (635,361 ) 147,794 Tenant improvements 42,689 (29,467 ) 13,222 Buildings and land 340 (73 ) 267 Total $ 926,956 $ (732,622 ) $ 194,334 Plant, property and equipment, net as of December 31, 2016 are as follows: Accumulated Net Carrying (in thousands) Cost Depreciation Amount Furniture and fixtures $ 4,905 $ (4,231 ) $ 674 Office equipment 80,384 (57,295 ) 23,089 Transportation and service equipment 16,140 (4,291 ) 11,849 Major equipment 794,153 (639,452 ) 154,701 Tenant improvements 43,888 (29,665 ) 14,223 Buildings and land 340 (62 ) 278 Total $ 939,810 $ (734,996 ) $ 204,814 Other accrued liabilities consisted of the following: (in thousands) March 31, 2017 December 31, 2016 Systems rental and maintenance costs $ 1,073 $ 1,064 Site rental fees 873 899 Property and sales taxes payable 7,537 7,254 Self-insurance accrual 2,705 2,612 Legal fees 1,921 1,537 Deferred gain on sale of equipment 87 87 Equipment purchases 446 848 Customer overpayments 2,149 2,555 Contingent consideration related to acquisitions 535 555 Mandatorily redeemable noncontrolling interest 2,386 2,386 Other accrued liabilities 7,944 9,526 Total $ 27,656 $ 29,323

Long-Term Debt and Senior Subor

Long-Term Debt and Senior Subordinated Credit Facility	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Long-Term Debt and Senior Subordinated Credit Facility	8. Long-Term Debt and Senior Subordinated Credit Facility Long-term debt consisted of the following: (in thousands) March 31, 2017 December 31, 2016 Term loan facility $ 496,374 $ 497,674 Discount on term loan facility (1,179 ) (1,310 ) Revolving loan facility 16,500 21,500 Equipment under capital leases 15,217 16,040 Equipment debt 38,607 39,343 Deferred financing costs, net (22,270 ) (24,502 ) Long-term debt, including current portion 543,249 548,745 Less current portion (22,916 ) (20,652 ) Long-term debt $ 520,333 $ 528,093 Equipment debt, collateralized by equipment, has interest rates ranging from 2.23% to 9.00% and are payable in various monthly principal and interest installments through 2021. Certain of the Company’s equipment debt obligations are subject to covenants with which it must comply on a quarterly or annual basis. An amendment to the financing agreement with Bank of the West (“BOW”) was executed on April 28, 2017, retroactive to March 31, 2017, that modified certain financial covenants. Based on such amendment, the Company was in compliance with all covenants as of March 31, 2017. Capital leases, collateralized by equipment, have interest rates ranging from 2.68% to 6.23% and are payable in various monthly principal and interest installments through 2021. Credit Facility and Senior Secured Term Loan Refinancing On June 3, 2013, the Company replaced its existing credit facility with a new senior secured credit agreement with Credit Suisse AG, Cayman Islands Branch, as administrative agent, and the other lenders party thereto (the “Credit Agreement”). The Credit Agreement consists of (i) a $340.0 million, six-year term loan facility, (ii) a $50.0 million, five-year revolving loan facility, including a $20.0 million sublimit for letters of credit, (iii) uncommitted incremental loan facilities of $100.0 million of revolving or term loans, plus an additional amount if the Company’s pro forma leverage ratio is less than or equal to 3.25, subject to receipt of lender commitments and satisfaction of specified conditions, and (iv) a $80.0 million delayed draw term loan facility, which was drawn within thirty days of June 3, 2013 and used for the redemption of the Company’s $190.0 million of 8% Senior Notes (“Notes”). The delayed draw term loan facility converted into, and matched the terms of, the $340.0 million term loan facility. On October 11, 2013, the Company entered into an amendment to the Credit Agreement (the “First Amendment”). Pursuant to the First Amendment, the Company raised $70.0 million On June 19, 2015, the Company entered into a second amendment to the Credit Agreement (the “Second Amendment”). Pursuant to the Second Amendment, the Company raised the remaining $30.0 million in incremental term loan commitments. The funds were used to repay all outstanding borrowings under the Company’s revolving loan facility, to pay fees and expenses related to the Second Amendment, and for general corporate purposes. The incremental term loan under the Second Amendment was funded at 99.5% of principal amount. Upon funding, the incremental term loans were converted to match all the terms of existing term loans. On March 29, 2016, the Company entered into a third amendment to the Credit Agreement (the “Third Amendment”). Pursuant to the Third Amendment, (i) the defined term “Investors” was amended to include THAIHOT so that the sale by the Selling Stockholders would not be deemed to constitute a change of control, and (ii) the soft call provision was reinstated to commence on the date the Third Amendment is effective and end the date that is twelve months after such commencement. Under the soft call provision, which expired on March 29, 2017, if the Company made a voluntary prepayment of any term loan or prepaid, refinanced, substituted or replaced any term loan, and such action resulted in a reduction in the effective interest cost or weighted average yield of the term loan, then the Company should pay to the administrative agent, for the ratable account of each of the lenders holding term loans, a prepayment premium equal to 1.0% of the aggregate principal amount of the term loans so prepaid, refinanced, substituted or replaced. In connection with the Third Amendment, the Company paid fees totaling $25.0 million, which were capitalized and amortized using the effective interest method as interest expense over the term of the Credit Agreement. These fees were paid by both the buyer and sellers in the Tahoe Transaction. Borrowings under the Credit Agreement bear interest through maturity at a variable rate based upon, at the Company’s option, either the LIBOR or the base rate (which is the highest of the administrative agent’s prime rate, one-half of 1.00% in excess of the overnight federal funds rate, and 1.00% in excess of the one-month LIBOR rate), plus, in each case, an applicable margin. With respect to the term loan facilities, the applicable margin for LIBOR loans is 3.25% per annum, and with respect to the revolving loan facility, the applicable margin for LIBOR loans ranges from 3.00% to 3.25% per annum, based on the applicable leverage ratio, and in each case, with a LIBOR floor of 1.00%. The applicable margin for base rate loans under the term loan facilities is 2.25% per annum and under the revolving loan facility ranges from 2.00% to 2.25% per annum, based on the applicable leverage ratio. The Company is required to pay a commitment fee which ranges from 0.38% to 0.50% per annum, based on the applicable leverage ratio, on the undrawn portion available under the revolving loan facility and variable per annum fees with respect to outstanding letters of credit. The Company is required to make quarterly amortization payments on the term loan of $1.3 million. The Company is also required to make mandatory prepayments of term loans under the Credit Agreement, subject to specified exceptions, from excess cash flow (as defined in the Credit Agreement) and with the proceeds of asset sales, debt issuances and specified other events. As of March 31, 2017, the Company had $29.2 million of available borrowings under the revolving loan facility, net of $16.5 million outstanding on the revolving loan facility and $4.3 million outstanding in letters of credit. Obligations under the Credit Agreement are guaranteed by substantially all the Company’s direct and indirect domestic subsidiaries. The obligations under the Credit Agreement and the guarantees are secured by a lien on substantially all tangible and intangible property, and by a pledge of all of the shares of stock and limited liability company interests of the Company’s direct and indirect domestic subsidiaries, of which the Company now owns or later acquires more than a 50% interest, subject to limited exceptions. In addition to other covenants, the Credit Agreement places limits on the ability of the Company and its subsidiaries to declare dividends or redeem or repurchase capital stock; prepay, redeem or purchase debt; incur liens and engage in sale-leaseback transactions; make loans and investments; incur additional indebtedness; amend or otherwise alter debt and other material agreements; engage in mergers, acquisitions and asset sales; transact with affiliates and alter the business conducted by the Company and its subsidiaries. The Credit Agreement also contains a leverage ratio covenant requiring the Company to maintain a maximum ratio of consolidated total debt to Consolidated Adjusted EBITDA, as defined in the Credit Agreement, that ranges from 4.95 to 1.00 to 4.30 to 1.00. At March 31, 2017, the Credit Agreement required a maximum leverage ratio of not more than 4.30 to 1.00. As of March 31, 2017, the Company’s ratio of consolidated total debt to Consolidated Adjusted EBITDA calculated pursuant to the Credit Agreement was 4.00 to 1.00. Failure to comply with the covenants in the Credit Agreement could permit the lenders under the Credit Agreement to declare all amounts borrowed under the Credit Agreement, together with accrued interest and fees, to be immediately due and payable and to terminate all commitments under the Credit Agreement. As of March 31, 2017, the Company was in compliance with the covenants for the Credit Agreement. Notes Payable and Line of Credit with PNC The Company had notes payable to PNC Equipment Finance, LLC (“PNC”) totaling $7.8 million at March 31, 2017. The notes payable are due in various installments through September 2021 at interest rates between 2.23% and 2.29% per annum. The notes are also collateralized by equipment and contain restrictive covenants. The Company also has a $3.0 million line of credit with PNC, with interest calculated based on LIBOR plus 1.50%. As of March 31, 2017, there was $0.5 million amount outstanding on the line of credit.

Derivatives

Derivatives	3 Months Ended
	Mar. 31, 2017
Summary Of Derivative Instruments [Abstract]
Derivatives	9. Derivatives Interest Rate Cash Flow Hedges The Company entered into multiple interest rate swap agreements to hedge the future cash interest payments on portions of its variable rate bank debt. For the three months ended March 31, 2017 and December 31, 2016, the Company had interest rate swap agreements to hedge approximately $14.1 million and $15.5 million of its variable rate bank debt, respectively, or 2.50% and 2.70% of total debt, respectively. The amount that the Company expects to reclassify from “Unrealized gain (loss) on hedging transactions, net of taxes” to “Interest expense, net” over the next twelve months is immaterial. The Company’s interest rate cash flow hedges consist of: Fair Value Asset (Liability) (1) (dollars in thousands) Notional Amount Fixed Payment Rate Maturity Date March 31, 2017 December 31, 2016 Liability Derivatives Derivatives designated as cash flow hedging instruments: One-month LIBOR plus 2.50 effective December 2012 $ 840 3.75% December 2017 $ — $ (3 ) One-month LIBOR plus 2.00% interest rate swap, effective March 2013 952 2.87% April 2018 1 — One-month LIBOR interest rate swap, effective December 2014 917 1.34% November 2019 1 (2 ) One-month LIBOR plus 2.00% interest rate swap, effective December 2015 4,430 3.69% December 2021 (8 ) (24 ) One-month LIBOR interest rate swap, effective December 2015 1,096 1.37% December 2020 3 — One-month LIBOR interest rate swap, effective September 2016 4,205 1.17% September 2021 43 33 Derivatives not designated as cash flow hedging instruments: One-month LIBOR interest rate swap 1,619 0.75% - 1.68% April 2017 - April 2020 2 (2 ) Total liability derivatives $ 14,059 $ 42 $ 2 (1) The fair values of the interest rate swap asset and liabilities are included in “Other assets” and “Other accrued liabilities,” respectively, in the condensed consolidated balance sheets. The following table summarizes the amount of income (loss) recognized from derivative instruments for the periods indicated and the line items in the accompanying condensed consolidated statements of operations and comprehensive loss where the results are recorded for cash flow hedges: Amount of Gain (Loss) Recognized in OCI on Derivatives (Effective Portion) Location of Loss Reclassified from Accumulated OCI into Income (Effective Portion) Amount of Loss (Gain) Reclassified from Accumulated OCI into Income (Effective Portion) Location of Gain (Loss) Recognized in Income on Derivatives (Ineffective Portion) Amount of Gain (Loss) Recognized in Income on Derivatives Income (Ineffective Portion) Three Months Ended March 31, Three Months Ended March 31, Three Months Ended March 31, (in thousands) 2017 2016 2017 2016 2017 2016 Interest rate contracts $ 13 $ (79 ) Interest expense, net $ 19 $ (83 ) Interest expense, net $ — $ — Total $ 13 $ (79 ) $ 19 $ (83 ) $ — $ — The effect of non-designated derivative instruments on the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2017 and 2016 was immaterial.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	10. Income Taxes For the three months ended March 31, 2017, the Company’s income tax benefit was immaterial. For the three months ended March 31, 2016, the Company recorded an income tax benefit of $0.9 million, which was 44.3% of the Company’s pre-tax loss . million of tax deficiencies recognized on stock-based compensation expense were reflected in the Company’s condensed consolidated statements of operations and comprehensive loss as a component of the benefit for income taxes rather than paid-in capital on a prospective basis during the three months ended March 31, 2017. See Note 2 for details. As of March 31, 2017 and December 31, 2016, the Company has provided a liability for $0.3 of unrecognized tax benefits related to various federal and state income tax matters. The tax-effected amount that would reduce the Company’s effective income tax rate if recognized is $0.2 million as of March 31, 2017 and December 31, 2016. The Company recognizes accrued interest and penalties related to unrecognized tax benefits in “Income tax expense (benefit).” Accrued interest and penalties related to unrecognized tax benefits as of March 31, 2017 and December 31, 2016 were not material. The Company is subject to U.S. federal income tax as well as income tax of multiple state tax jurisdictions. The Company is currently open to audit under the statute of limitations by the Internal Revenue Service for the years ended December 31, 2013 through 2016. The Company’s and its subsidiaries’ state income tax returns are open to audit under the applicable statutes of limitations for the years ended December 31, 2012 through 2016. The Company does not anticipate a significant change to the total amount of unrecognized tax benefits within the next 12 months.

Loss Per Common Share

Loss Per Common Share	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Loss Per Common Share	11. Loss Per Common Share The following table sets forth the computation of basic and diluted net loss per share: Three Months Ended March 31, (in thousands, except per share amounts) 2017 2016 Numerator: Net loss attributable to Alliance HealthCare Services, Inc. $ (614 ) $ (1,190 ) Denominator: Weighted average shares — 10,973 10,779 Effect of dilutive securities: Stock options and RSUs — — Weighted average shares — diluted 10,973 10,779 Net loss per common share attributable to Alliance HealthCare Services, Inc.: Basic $ (0.06 ) $ (0.11 ) Diluted $ (0.06 ) $ (0.11 ) Stock options excluded from the computation of diluted per share amounts: Weighted average shares for which the exercise price exceeds average market price of common stock 323 465 Average exercise price per share that exceeds average market price of common stock $ 29.37 $ 25.34

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	12. Commitments and Contingencies Purchase Commitments The Company has maintenance contracts with its equipment vendors and other service providers for substantially all of its radiology and oncology equipment. The contracts range from 1 to 5 years from inception and extend through the year 2021, but may be canceled by the Company under certain circumstances. The Company’s total contract payments were $11.1 million and $10.3 million for the three months ended March 31, 2017 and 2016, respectively. At March 31, 2017, the Company had binding equipment purchase commitments totaling $15.2 million. Guarantees and Indemnities The Company has applied the disclosure provisions of ASC 460, “Guarantees,” to its agreements that contain guarantee or indemnification clauses. These disclosure provisions expand those required by ASC 440, “Commitments,” and ASC 450, “Contingencies,” by requiring a guarantor to disclose certain types of guarantees, even if the likelihood of requiring the guarantor’s performance is remote. In the normal course of business, the Company has made certain guarantees and indemnities, under which it may be required to make payments to a guaranteed or indemnified party, in relation to certain transactions. The Company indemnifies other parties, including customers, lessors, and parties to other transactions with the Company, with respect to certain matters. The Company has agreed to hold the other party harmless against losses arising from certain events as defined within the particular contract, which may include, for example, litigation or claims arising from a breach of representations or covenants. In addition, the Company has entered into indemnification agreements with its executive officers and directors and the Company’s bylaws contain similar indemnification obligations. Under these arrangements, the Company is obligated to indemnify, to the fullest extent permitted under applicable law, its current or former officers and directors for various amounts incurred with respect to actions, suits or proceedings in which they were made, or threatened to be made, a party as a result of acting as an officer or director. It is not possible to determine the maximum potential amount under these indemnification agreements due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement. Historically, payments made related to these indemnifications have been immaterial. At March 31, 2017, the Company has determined that no liability is necessary related to these guarantees and indemnities. Litigation In November 2015, the Company was served with a lawsuit in the United States District Court for the Northern District of Ohio by Todd S. Elwert, DC, Inc. The Complaint alleges violations of the Junk Fax Prevention Act for allegedly sending an unsolicited advertisement to Plaintiff which promoted commercial availability and/or quality of the Company’s services. The Plaintiff further alleges that it is part of a class of similarly situated chiropractors who received the blast fax, and as such, requested class certification. The Company filed its response on December 17, 2015 and is currently in the discovery phase of the lawsuit. The Company intends to vigorously defend itself against the lawsuit and currently believes the ultimate disposition of these matters will not have a material adverse effect on its consolidated financial statements. Other Matters The Company is involved from time to time in routine litigation and regulatory matters incidental to the conduct of its business. The Company believes that resolution of such matters will not have a material adverse effect on its consolidated financial statements.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions	13. Related Party Transactions Ownership Structure On September 16, 2015, Tahoe agreed to purchase approximately 5,537,945 shares of the Company’s common stock from funds managed by the Selling Stockholders. Tahoe, through a wholly-owned subsidiary, owned an aggregate of approximately of the Company’s outstanding shares of common stock as of March 31, 2017. On April 10, 2017, the Company entered into a Merger Agreement with the Purchaser Parties, pursuant to which the Purchaser Parties will acquire all of the Company’s outstanding common stock that is not beneficially owned by Tahoe or owned by the Company as treasury shares. See Note 1 and Note 17 for details. Management Agreements The Company had direct ownership in two unconsolidated investees at March 31, 2017 and December 31, 2016. The following table summarizes revenues from management agreements with unconsolidated equity investees: Three Months Ended March 31, (in thousands) 2017 2016 Revenue from management agreements $ 474 $ 353 The Company provides services as part of its ongoing operations for and on behalf of the unconsolidated equity investees, which are included in the management agreement revenue, and reimburse the Company for the actual amount of the expenses incurred. The Company records the expenses as cost of revenues and the reimbursement as revenue in its condensed consolidated statements of operations and comprehensive loss. The following table summarizes the revenue and reimbursed expenses related to the Company’s unconsolidated equity investees: Three Months Ended March 31, (in thousands) 2017 2016 Revenue and reimbursed expenses $ 363 $ 252

Investments in Unconsolidated I

Investments in Unconsolidated Investees	3 Months Ended
	Mar. 31, 2017
Equity Method Investments And Joint Ventures [Abstract]
Investments in Unconsolidated Investees	14. Investments in Unconsolidated Investees The Company has direct ownership in two unconsolidated investees at March 31, 2017. The Company owns 15% and 50% of these investees, respectively, and provides management services under agreements with these investees, expiring at various dates through 2025. Both of these investees are accounted for under the equity method because the Company does not exercise control over the operations of these investees. Set forth below are certain balance sheet data as of March 31, 2017 and 2016 and operating results for the three months ended March 31, 2017 and 2016 for the aggregate of the Company’s unconsolidated investees. (in thousands) March 31, 2017 December 31, 2016 Balance sheet data: Current assets $ 3,841 $ 2,860 Noncurrent assets 84 111 Current liabilities 660 760 Noncurrent liabilities 31 32 Three Months Ended March 31, (in thousands) 2017 2016 Operating results: Revenues $ 2,593 $ 2,301 Expenses 790 778 Net income 1,803 1,523 Earnings from unconsolidated investees 336 252

Stockholders' Deficit

Stockholders' Deficit	3 Months Ended
	Mar. 31, 2017
Stockholders Equity Note [Abstract]
Stockholders' Deficit	15. Stockholders’ Deficit The following table summarizes changes in the Company’s consolidated stockholders’ deficit, including noncontrolling interest, during the three months ended March 31, 2017. Stockholders’ (Deficit) Equity Attributable to Common Stock Treasury Stock Additional Paid-In Accumulated Comprehensive Accumulated Alliance HealthCare Non-controlling Total Stockholders’ (Deficit) (dollars in thousands) Shares Amount Shares Amount Capital Income Deficit Services, Inc. Interest Equity Balance at December 31, 2016 10,970,937 $ 110 (157,973 ) $ (3,138 ) $ 61,353 $ 10 $ (197,900 ) $ (139,565 ) $ 130,062 $ (9,503 ) Vesting of stock awards, net 18,336 — — — — — — — — — Share-based payment — — — — 381 — — 381 — 381 Other comprehensive income — — — — — 32 — 32 — 32 Distributions to noncontrolling interest in subsidiaries — — — — — — — — (5,600 ) (5,600 ) Contributions from noncontrolling interest in subsidiaries — — — — — — — — 286 286 Net (loss) income — — — — — — (614 ) (614 ) 5,075 4,461 Balance at March 31, 2017 10,989,273 $ 110 (157,973 ) $ (3,138 ) $ 61,734 $ 42 $ (198,514 ) $ (139,766 ) $ 129,823 $ (9,943 ) The following table summarizes changes in the Company’s consolidated stockholders’ deficit, including noncontrolling interest, during the three months ended March 31, 2016. Stockholders’ (Deficit) Equity Attributable to Common Stock Treasury Stock Additional Paid-In Accumulated Comprehensive Accumulated Alliance HealthCare Non-controlling Total Stockholders’ (Deficit) (dollars in thousands) Shares Amount Shares Amount Capital Loss Deficit Services, Inc. Interest Equity Balance at December 31, 2015 10,774,857 $ 108 (157,973 ) $ (3,138 ) $ 29,297 $ (511 ) $ (198,393 ) $ (172,637 ) $ 95,017 $ (77,620 ) Exercise of stock options 100,000 1 — — 485 — — 486 — 486 Shareholder transaction — — — — 28,629 — — 28,629 — 28,629 Share-based payment — — — — 1,402 — — 1,402 — 1,402 Share-based payment income tax benefit — — — — 345 — — 345 — 345 Other comprehensive loss — — — — — (38 ) — (38 ) — (38 ) Distributions to noncontrolling interest in subsidiaries — — — — — — — — (2,433 ) (2,433 ) Net (loss) income — — — — — — (1,190 ) (1,190 ) 4,592 3,402 Balance at March 31, 2016 10,874,857 $ 109 (157,973 ) $ (3,138 ) $ 60,158 $ (549 ) $ (199,583 ) $ (143,003 ) $ 97,176 $ (45,827 )

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2017
Segment Reporting [Abstract]
Segment Information	16. Segment Information In accordance with ASC 280, “Segment Reporting,” and based on the nature of the financial information that is received by the chief operating decision maker (“CODM”), the Company operates in three operating segments (Radiology, Oncology and Interventional) that also qualify as reportable segments under the definition of ASC 280. Each of these reportable segments, on a stand-alone basis, provides and makes available their respective medical services in similar settings and operates within a singular regulatory environment. Further, management assesses the segment operations and each segment’s degree of efficiency and performance based on this structure of financial reporting and primarily makes operating decisions from these reportable segment results. The Radiology segment is comprised of diagnostic imaging services including MRI, PET/CT and other imaging services. The Oncology segment is comprised of radiation oncology services. The Interventional segment is comprised of therapeutic, minimally invasive pain management procedures and services. All intercompany revenues, expenses, payables, and receivables are eliminated in consolidation and are not reviewed when evaluating segment performance. Each segment’s performance is evaluated based on revenue and Adjusted EBITDA. The following table summarizes the Company’s revenue by segment: Three Months Ended March 31, (in thousands) 2017 2016 Revenue: MRI revenue 49,455 $ 47,570 PET/CT revenue 32,180 31,666 Other radiology 6,177 6,403 Radiology 87,812 85,639 Oncology 30,033 26,062 Interventional 11,652 11,663 Corporate / Other 439 361 Total $ 129,936 $ 123,725 Adjusted EBITDA represents net income before: income taxes; net income attributable to noncontrolling interest; interest expense, net; depreciation expense; amortization expense; share-based payment; severance and related costs; restructuring charges; transaction costs; shareholder transaction costs; legal matters expense, net; changes in fair value of contingent consideration related to acquisitions; and other non-cash (benefits) charges, net. Adjusted EBITDA is the most frequently used measure of each segment’s performance and is commonly used in setting performance goals. The following table summarizes the Company’s Adjusted EBITDA by segment: Three Months Ended March 31, (in thousands) 2017 2016 Adjusted EBITDA: Radiology $ 29,205 $ 26,443 Oncology 13,808 12,157 Interventional 1,055 1,255 Corporate / Other (11,310 ) (9,483 ) Total $ 32,758 $ 30,372 The reconciliation of income before income taxes, earnings from unconsolidated investees, and noncontrolling interest to total Adjusted EBITDA is shown below: Three Months Ended March 31, (in thousands) 2017 2016 Income before income taxes, earnings from unconsolidated investees, and noncontrolling interest $ 4,122 $ 2,205 Earnings from unconsolidated investees 336 252 Interest expense, net 8,700 7,495 Depreciation expense 14,073 13,048 Amortization expense 3,275 2,443 Share-based payment (included in “ ” 381 1,865 Severance and related costs 634 1,716 Restructuring charges (Note 3) 215 231 Transaction costs 162 417 Shareholder transaction costs 869 1,009 Legal matters expense, net (included in “Selling, general and administrative expenses”) — 155 Changes in fair value of contingent consideration related to acquisitions (included in “Other income, net”) — (600 ) Other non-cash (benefits) charges, net (included in “Other income, net”) (9 ) 136 Total Adjusted EBITDA $ 32,758 $ 30,372 The following table summarizes the Company’s identifiable assets by segment: March 31, December 31, (in thousands) 2017 2016 Identifiable assets: Radiology $ 290,480 $ 301,137 Oncology 251,382 256,456 Interventional 81,288 82,221 Corporate / Other 22,492 20,050 Total $ 645,642 $ 659,864 The following table summarizes the Company’s equipment capital expenditures by segment: Three Months Ended March 31, (in thousands) 2017 2016 Capital expenditures: Radiology $ 812 $ 16,926 Oncology 12 484 Interventional 15 33 Corporate / Other — 232 Total $ 839 $ 17,675

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	17. Subsequent Events Merger Agreement As discussed in Note 1, on April 10, 2017, the Company entered into a Merger Agreement with the Purchaser Parties, pursuant to which Tahoe will acquire all of the Company’s outstanding common stock that is not beneficially owned by Tahoe or owned by the Company as treasury shares, for $13.25 per share. The Company’s board of directors, acting on the unanimous recommendation of a special committee, comprised solely of independent and disinterested directors of the Company who are not affiliated with Tahoe or management of the Company (the “Special Committee”), approved the Merger Agreement and the transactions At the effective time of the Merger, each issued and outstanding share of common stock, other than shares owned by Alliance as treasury stock, shares beneficially owned by the Purchaser Parties, and shares owned by holders of common stock who shall neither have voted in favor of the Merger nor consented thereto in writing and who shall have properly and validly perfected, and not effectively withdrawn or lost, their statutory appraisal rights under Delaware law (such shares of common stock “dissenting shares”), will be converted into the right to receive $13.25 in cash per share, without interest and subject to any withholding taxes (the “Merger Consideration”). Under the terms of the Merger Agreement, each in-the-money stock option, whether or not exercisable or vested, will be converted into the right to receive the excess of the Merger Consideration over the option exercise price. RSUs that are not subject to accelerated vesting in accordance with their terms will be converted into the right to receive restricted cash awards equal to the Merger Consideration multiplied by the number of shares underlying the RSUs and shall continue to be subject to the same vesting and payment conditions and schedules applicable to such RSUs. The Purchaser Parties have informed Alliance that they intend to fund the payment of the aggregate Merger Consideration from cash on hand. The Merger is not subject to a financing condition. The Merger Agreement contains certain termination rights for both Alliance and Parent, and further provides that upon the termination of the Merger Agreement under certain circumstances, Alliance will be required to pay Parent an expense reimbursement amount equal to $1.5 million in immediately available funds or Parent will be required to pay Alliance an expense reimbursement amount equal to $4.5 million in immediately available funds (as applicable). Subject to certain limitations, either Alliance or Parent may terminate the Merger Agreement if the Merger is not consummated by December 15, 2017 (the “Termination Date”); provided that the Company may extend the Termination Date for a single additional 60-day period under certain circumstances. In connection with the Merger, the Special Committee waived the standstill provisions of the Governance, Voting and Standstill Agreement, dated March 29, 2016, by and among Alliance, THAIHOT and Tahoe solely for the purpose of permitting the Purchaser Parties to enter into the Merger Agreement, perform the Purchaser Parties’ obligations thereunder, and consummate the contemplated transactions. Upon closing of the Merger, Alliance is expected to remain headquartered in Southern California. Alliance’s executive management team is expected to remain in place. All of Alliance’s divisions within the United States are expected to continue unaffected.

Basis of Presentation, Princi24

Basis of Presentation, Principles of Consolidation, and Use of Estimates (Policies)	3 Months Ended
	Mar. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements have been prepared by Alliance HealthCare Services, Inc. (the “Company” or “Alliance”) in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. The accompanying condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes to the consolidated financial statements for the year ended December 31, 2016. For a complete summary
Pending Transaction	Pending Transaction On April 10, 2017, the Company entered into an agreement and plan of merger (the “Merger Agreement”) by and among Tahoe Investment Group Co., Ltd., an entity organized under the laws of the People’s Republic of China (“Tahoe”), THAIHOT Investment Company Limited, an exempted company incorporated under the laws of the Cayman Islands and indirect wholly-owned subsidiary of Tahoe (“THAIHOT”), THAIHOT Investment Company US Limited, a Delaware corporation and indirect wholly-owned subsidiary of Tahoe (“Parent”) and Alliance Healthcare Services Merger Sub Limited, a Delaware corporation and wholly-owned subsidiary of Parent (“Sub” and together with Tahoe, THAIHOT and Parent, the “Purchaser Parties”) providing for the merger of Sub with and into Alliance (the “Merger”), with Alliance surviving the Merger as a wholly-owned subsidiary of Parent. Under the Merger Agreement, the Purchaser Parties will acquire all of the Company’s outstanding common stock that is not beneficially owned by the Purchaser Parties or owned by the Company as treasury shares. The Merger is subject to approval by Alliance’s stockholders, including a non-waiveable condition requiring approval by the holders of a majority of the outstanding shares of Alliance common stock that are not beneficially owned by the Purchaser Parties or certain senior executive officers of the Company, as well as certain other customary closing conditions. The Merger is not subject to a financing condition. The Company will call a meeting of stockholders for the purpose of voting on the adoption of the Merger Agreement in due course. If completed, the Merger will result in the Company becoming a privately held company and Alliance’s common stock would no longer be listed on NASDAQ. See Note 17 for details.
Principles of Consolidation	Principles of Consolidation The accompanying condensed consolidated financial statements of the Company include the assets, liabilities, revenues and expenses of all subsidiaries over which the Company exercises control. Intercompany transactions have been eliminated. The Company evaluates participating rights in its assessment of control in determining consolidation of joint venture partners. The Company records noncontrolling interest related to its consolidated subsidiaries that are not wholly-owned. Investments in unconsolidated investees over which it exercises significant influence but does not control are accounted for under the equity method.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

Transactions (Tables)

Transactions (Tables)	3 Months Ended
	Mar. 31, 2017
Business Combinations Restructuring And Related Activities [Abstract]
Restructuring Charges	From time to time, the Company’s management implements individually immaterial restructuring plans, including the closure or consolidation of certain sites as a result of the loss of certain customers. The impact of the charges resulting from restructuring plans are summarized below: Three Months Ended March 31, (in thousands) 2017 2016 Cost of revenues, excluding depreciation and amortization $ 77 $ 200 Selling, general and administrative expenses 19 31 Other expense, net 119 — Total restructuring charges $ 215 $ 231

Share-Based Payment (Tables)

Share-Based Payment (Tables)	3 Months Ended
	Mar. 31, 2017
Share Based Compensation [Abstract]
Weighted Average Assumptions For Stock Option Awards	The following weighted average assumptions were used in the estimated grant date fair value calculations for stock option awards: Three Months Ended March 31, 2016 Risk free interest rate 1.53 % Expected dividend yield — % Expected stock price volatility 66.5 % Average expected life (in years) 6.00 Weighted average fair value on grant date $ 7.16
Summary of Stock Option Activity	The following table summarizes the Company’s stock option activity: (dollars in thousands, except per share amounts) Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (1) Outstanding at December 31, 2016 650,969 $ 18.51 Canceled/forfeited (26,242 ) 34.23 Outstanding at March 31, 2017 624,727 17.85 6.34 $ 1,119 Vested and expected to vest in the future at March 31, 2017 598,945 18.31 6.22 $ 1,039 Vested and exercisable at March 31, 2017 500,086 20.51 5.68 $ 736 (1) Represents the difference between the exercise price and the value of the Company’s stock at fiscal quarter-end.
Summary of Unvested Stock Option Activity	The following table summarizes the Company’s unvested stock option activity: (dollars in thousands, except per share amounts) Shares Weighted Average Grant-Date Fair Value Aggregate Unrecognized Compensation Weighted Average Period Over Which Expected to be Recognized (in years) Total Fair Value Unvested at December 31, 2016 187,804 $ 4.33 Vested (62,303 ) 4.33 $ 270 Forfeited (860 ) 4.18 Unvested at March 31, 2017 124,641 $ 4.33 $ 421 2.0
Summary of Unvested RSU Activity	The following table summarizes the Company’s RSU activity: (dollars in thousands, except per share amounts) Shares Weighted Average Grant-Date Fair Value Aggregate Unrecognized Compensation Weighted Average Period Over Which Expected to be Recognized (in years) Unvested at December 31, 2016 167,853 $ 8.37 Vested (25,690 ) 6.93 Forfeited (519 ) 6.93 Unvested at March 31, 2017 141,644 $ 8.63 $ 929 1.1
Summary of Pre-tax Share-based Compensation Expense	The following table summarizes pre-tax share-based compensation expense included within “Selling, general and administrative expenses” in the condensed consolidated statements of operations and comprehensive loss: Three Months Ended March 31, (in thousands) 2017 2016 Share-based compensation expense $ 381 $ 1,865 (1) (1) Decrease in share-based compensation expense was primarily due to additional expense recognized during the three months ended March 31, 2016 related to a change in control in connection with the Tahoe Transaction in March 2016 (see Note 3). This includes cash paid of $463 related to market performance RSUs, granted to executive management, which vested upon a change in control of the Company under the terms of the RSU award agreement.

Fair Value of Financial Instr27

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Summary of Valuation of Financial Instruments Reported at Fair Value on a Recurring Basis	The following table summarizes the valuation of the Company’s financial instruments that are reported at fair value on a recurring basis: Fair Value as of March 31, 2017 Fair Value as of December 31, 2016 (in thousands) Total Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Financial assets: Interest rate contracts - asset position $ 68 $ — $ 68 $ — $ 55 $ — $ 55 $ — Total financial assets $ 68 $ — $ 68 $ — $ 55 $ — $ 55 $ — Financial liabilities: Contingent consideration related to acquisitions $ 535 $ — $ — $ 535 $ 555 $ — $ — $ 555 Mandatorily redeemable noncontrolling interest 2,386 — — 2,386 2,386 — — 2,386 Interest rate contracts - liability position 26 — 26 — 53 — 53 — Total financial liabilities $ 2,947 $ — $ 26 $ 2,921 $ 2,994 $ — $ 53 $ 2,941 Financial instruments measured and recorded at fair value on a recurring basis were presented on the Company’s consolidated balance sheets as follows: Fair Value as of March 31, 2017 Fair Value as of December 31, 2016 (in thousands) Total Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Financial assets: Other assets $ 68 $ — $ 68 $ — $ 55 $ — $ 55 $ — Total financial assets $ 68 $ — $ 68 $ — $ 55 $ — $ 55 $ — Financial liabilities: Other accrued liabilities $ 2,947 $ — $ 26 $ 2,921 $ 2,994 $ — $ 53 $ 2,941 Total financial liabilities $ 2,947 $ — $ 26 $ 2,921 $ 2,994 $ — $ 53 $ 2,941
Schedule of Changes in Fair Value of Level 3 Liabilities	Changes in the fair value of the Company’s Level 3 liabilities for the three months ended March 31, 2017 were as follows: (in thousands) Contingent consideration related to acquisitions Mandatorily redeemable noncontrolling interest Balance at December 31, 2016 $ 555 $ 2,386 Settlement (20 ) — Balance at March 31, 2017 $ 535 $ 2,386
Summary of Fair Values and Book Values of Fixed and Variable-rate Long-term Debt	The following table summarizes the fair values and book values of the Company’s long-term debt: March 31, 2017 December 31, 2016 (in thousands) Fair Value Book Value Fair Value Book Value Variable-rate debt $ 526,447 $ 528,879 $ 526,475 $ 533,939 Fixed-rate debt 38,617 36,640 41,572 39,308 $ 565,064 $ 565,519 $ 568,047 $ 573,247

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Changes in the Carrying Amount of Goodwill	Changes in the carrying amount of goodwill are as follows: (in thousands) Radiology Oncology Interventional Total Balance at December 31, 2016 $ 45,157 $ 42,320 $ 31,653 $ 119,130 Goodwill acquired during the period — — — — Adjustments to goodwill during the period — — — — Balance at March 31, 2017 $ 45,157 $ 42,320 $ 31,653 $ 119,130 Gross goodwill $ 199,499 $ 62,222 $ 31,653 $ 293,374 Accumulated impairment charges (154,342 ) (19,902 ) — (174,244 ) Balance at March 31, 2017 $ 45,157 $ 42,320 $ 31,653 $ 119,130
Components of Intangible Assets	Intangible assets consisted of the following: Weighted Average March 31, 2017 December 31, 2016 (dollars in thousands) Useful Life (in years) Gross Carrying Amount Accumulated Amortization Intangible Assets, Net Gross Carrying Amount Accumulated Amortization Intangible Assets, Net Finite-lived intangible assets: Customer contracts 16 $ 230,323 $ (104,179 ) $ 126,144 $ 230,323 $ (101,240 ) $ 129,083 Other 18 41,820 (22,480 ) 19,340 41,820 (22,141 ) 19,679 Total finite-lived intangible assets 16 $ 272,143 $ (126,659 ) $ 145,484 $ 272,143 $ (123,381 ) $ 148,762 Indefinite-lived intangible assets 50,215 50,215 Total other intangible assets $ 195,699 $ 198,977
Estimated Future Amortization Expense	Amortization expense for finite-lived intangible assets is reported as “Amortization expense” in the consolidated statements of operations and comprehensive loss. As of March 31, 2017, estimated future amortization expense for each of the fiscal years ending December 31, is presented below: (in thousands) Remainder of 2017 $ 9,784 2018 12,689 2019 12,200 2020 11,710 2021 10,802 Thereafter 88,299 $ 145,484

Supplemental Balance Sheet In29

Supplemental Balance Sheet Information (Tables)	3 Months Ended
	Mar. 31, 2017
Supplemental Balance Sheet Information [Abstract]
Plant, Property and Equipment, Net	Plant, property and equipment, net as of March 31, 2017 are as follows: Accumulated Net Carrying (in thousands) Cost Depreciation Amount Furniture and fixtures $ 4,835 $ (4,202 ) $ 633 Office equipment 80,284 (58,943 ) 21,341 Transportation and service equipment 15,653 (4,576 ) 11,077 Major equipment 783,155 (635,361 ) 147,794 Tenant improvements 42,689 (29,467 ) 13,222 Buildings and land 340 (73 ) 267 Total $ 926,956 $ (732,622 ) $ 194,334 Plant, property and equipment, net as of December 31, 2016 are as follows: Accumulated Net Carrying (in thousands) Cost Depreciation Amount Furniture and fixtures $ 4,905 $ (4,231 ) $ 674 Office equipment 80,384 (57,295 ) 23,089 Transportation and service equipment 16,140 (4,291 ) 11,849 Major equipment 794,153 (639,452 ) 154,701 Tenant improvements 43,888 (29,665 ) 14,223 Buildings and land 340 (62 ) 278 Total $ 939,810 $ (734,996 ) $ 204,814
Components of Other Accrued Liabilities	Other accrued liabilities consisted of the following: (in thousands) March 31, 2017 December 31, 2016 Systems rental and maintenance costs $ 1,073 $ 1,064 Site rental fees 873 899 Property and sales taxes payable 7,537 7,254 Self-insurance accrual 2,705 2,612 Legal fees 1,921 1,537 Deferred gain on sale of equipment 87 87 Equipment purchases 446 848 Customer overpayments 2,149 2,555 Contingent consideration related to acquisitions 535 555 Mandatorily redeemable noncontrolling interest 2,386 2,386 Other accrued liabilities 7,944 9,526 Total $ 27,656 $ 29,323

Long-Term Debt and Senior Sub30

Long-Term Debt and Senior Subordinated Credit Facility (Tables)	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Components of Long-term Debt	Long-term debt consisted of the following: (in thousands) March 31, 2017 December 31, 2016 Term loan facility $ 496,374 $ 497,674 Discount on term loan facility (1,179 ) (1,310 ) Revolving loan facility 16,500 21,500 Equipment under capital leases 15,217 16,040 Equipment debt 38,607 39,343 Deferred financing costs, net (22,270 ) (24,502 ) Long-term debt, including current portion 543,249 548,745 Less current portion (22,916 ) (20,652 ) Long-term debt $ 520,333 $ 528,093

Derivatives (Tables)

Derivatives (Tables)	3 Months Ended
	Mar. 31, 2017
Summary Of Derivative Instruments [Abstract]
Summary of Interest Rate Cash Flow Hedges	The Company’s interest rate cash flow hedges consist of: Fair Value Asset (Liability) (1) (dollars in thousands) Notional Amount Fixed Payment Rate Maturity Date March 31, 2017 December 31, 2016 Liability Derivatives Derivatives designated as cash flow hedging instruments: One-month LIBOR plus 2.50 effective December 2012 $ 840 3.75% December 2017 $ — $ (3 ) One-month LIBOR plus 2.00% interest rate swap, effective March 2013 952 2.87% April 2018 1 — One-month LIBOR interest rate swap, effective December 2014 917 1.34% November 2019 1 (2 ) One-month LIBOR plus 2.00% interest rate swap, effective December 2015 4,430 3.69% December 2021 (8 ) (24 ) One-month LIBOR interest rate swap, effective December 2015 1,096 1.37% December 2020 3 — One-month LIBOR interest rate swap, effective September 2016 4,205 1.17% September 2021 43 33 Derivatives not designated as cash flow hedging instruments: One-month LIBOR interest rate swap 1,619 0.75% - 1.68% April 2017 - April 2020 2 (2 ) Total liability derivatives $ 14,059 $ 42 $ 2 (1) The fair values of the interest rate swap asset and liabilities are included in “Other assets” and “Other accrued liabilities,” respectively, in the condensed consolidated balance sheets.
Effect of Designated Derivative Instruments on the Condensed Consolidated Statements of Operations and Comprehensive Loss	The following table summarizes the amount of income (loss) recognized from derivative instruments for the periods indicated and the line items in the accompanying condensed consolidated statements of operations and comprehensive loss where the results are recorded for cash flow hedges: Amount of Gain (Loss) Recognized in OCI on Derivatives (Effective Portion) Location of Loss Reclassified from Accumulated OCI into Income (Effective Portion) Amount of Loss (Gain) Reclassified from Accumulated OCI into Income (Effective Portion) Location of Gain (Loss) Recognized in Income on Derivatives (Ineffective Portion) Amount of Gain (Loss) Recognized in Income on Derivatives Income (Ineffective Portion) Three Months Ended March 31, Three Months Ended March 31, Three Months Ended March 31, (in thousands) 2017 2016 2017 2016 2017 2016 Interest rate contracts $ 13 $ (79 ) Interest expense, net $ 19 $ (83 ) Interest expense, net $ — $ — Total $ 13 $ (79 ) $ 19 $ (83 ) $ — $ —

Loss Per Common Share (Tables)

Loss Per Common Share (Tables)	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Computation of Basic and Diluted Net Loss Per Share	The following table sets forth the computation of basic and diluted net loss per share: Three Months Ended March 31, (in thousands, except per share amounts) 2017 2016 Numerator: Net loss attributable to Alliance HealthCare Services, Inc. $ (614 ) $ (1,190 ) Denominator: Weighted average shares — 10,973 10,779 Effect of dilutive securities: Stock options and RSUs — — Weighted average shares — diluted 10,973 10,779 Net loss per common share attributable to Alliance HealthCare Services, Inc.: Basic $ (0.06 ) $ (0.11 ) Diluted $ (0.06 ) $ (0.11 ) Stock options excluded from the computation of diluted per share amounts: Weighted average shares for which the exercise price exceeds average market price of common stock 323 465 Average exercise price per share that exceeds average market price of common stock $ 29.37 $ 25.34

Related Party Transactions (Tab

Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2017
Related Party Transactions [Abstract]
Summary of Revenue and Reimbursed Expenses with Unconsolidated Equity Investees	The following table summarizes revenues from management agreements with unconsolidated equity investees: Three Months Ended March 31, (in thousands) 2017 2016 Revenue from management agreements $ 474 $ 353 The following table summarizes the revenue and reimbursed expenses related to the Company’s unconsolidated equity investees: Three Months Ended March 31, (in thousands) 2017 2016 Revenue and reimbursed expenses $ 363 $ 252

Investments in Unconsolidated34

Investments in Unconsolidated Investees (Tables)	3 Months Ended
	Mar. 31, 2017
Equity Method Investments And Joint Ventures [Abstract]
Schedule of Financial Data of Unconsolidated Investees	Set forth below are certain balance sheet data as of March 31, 2017 and 2016 and operating results for the three months ended March 31, 2017 and 2016 for the aggregate of the Company’s unconsolidated investees. (in thousands) March 31, 2017 December 31, 2016 Balance sheet data: Current assets $ 3,841 $ 2,860 Noncurrent assets 84 111 Current liabilities 660 760 Noncurrent liabilities 31 32 Three Months Ended March 31, (in thousands) 2017 2016 Operating results: Revenues $ 2,593 $ 2,301 Expenses 790 778 Net income 1,803 1,523 Earnings from unconsolidated investees 336 252

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	3 Months Ended
	Mar. 31, 2017
Stockholders Equity Note [Abstract]
Summary of stockholders' deficit, including noncontrolling interest	The following table summarizes changes in the Company’s consolidated stockholders’ deficit, including noncontrolling interest, during the three months ended March 31, 2017. Stockholders’ (Deficit) Equity Attributable to Common Stock Treasury Stock Additional Paid-In Accumulated Comprehensive Accumulated Alliance HealthCare Non-controlling Total Stockholders’ (Deficit) (dollars in thousands) Shares Amount Shares Amount Capital Income Deficit Services, Inc. Interest Equity Balance at December 31, 2016 10,970,937 $ 110 (157,973 ) $ (3,138 ) $ 61,353 $ 10 $ (197,900 ) $ (139,565 ) $ 130,062 $ (9,503 ) Vesting of stock awards, net 18,336 — — — — — — — — — Share-based payment — — — — 381 — — 381 — 381 Other comprehensive income — — — — — 32 — 32 — 32 Distributions to noncontrolling interest in subsidiaries — — — — — — — — (5,600 ) (5,600 ) Contributions from noncontrolling interest in subsidiaries — — — — — — — — 286 286 Net (loss) income — — — — — — (614 ) (614 ) 5,075 4,461 Balance at March 31, 2017 10,989,273 $ 110 (157,973 ) $ (3,138 ) $ 61,734 $ 42 $ (198,514 ) $ (139,766 ) $ 129,823 $ (9,943 ) The following table summarizes changes in the Company’s consolidated stockholders’ deficit, including noncontrolling interest, during the three months ended March 31, 2016. Stockholders’ (Deficit) Equity Attributable to Common Stock Treasury Stock Additional Paid-In Accumulated Comprehensive Accumulated Alliance HealthCare Non-controlling Total Stockholders’ (Deficit) (dollars in thousands) Shares Amount Shares Amount Capital Loss Deficit Services, Inc. Interest Equity Balance at December 31, 2015 10,774,857 $ 108 (157,973 ) $ (3,138 ) $ 29,297 $ (511 ) $ (198,393 ) $ (172,637 ) $ 95,017 $ (77,620 ) Exercise of stock options 100,000 1 — — 485 — — 486 — 486 Shareholder transaction — — — — 28,629 — — 28,629 — 28,629 Share-based payment — — — — 1,402 — — 1,402 — 1,402 Share-based payment income tax benefit — — — — 345 — — 345 — 345 Other comprehensive loss — — — — — (38 ) — (38 ) — (38 ) Distributions to noncontrolling interest in subsidiaries — — — — — — — — (2,433 ) (2,433 ) Net (loss) income — — — — — — (1,190 ) (1,190 ) 4,592 3,402 Balance at March 31, 2016 10,874,857 $ 109 (157,973 ) $ (3,138 ) $ 60,158 $ (549 ) $ (199,583 ) $ (143,003 ) $ 97,176 $ (45,827 )

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2017
Segment Reporting [Abstract]
Summary of Revenue By Segment	The following table summarizes the Company’s revenue by segment: Three Months Ended March 31, (in thousands) 2017 2016 Revenue: MRI revenue 49,455 $ 47,570 PET/CT revenue 32,180 31,666 Other radiology 6,177 6,403 Radiology 87,812 85,639 Oncology 30,033 26,062 Interventional 11,652 11,663 Corporate / Other 439 361 Total $ 129,936 $ 123,725
Summary of Adjusted EBITDA By Segment	The following table summarizes the Company’s Adjusted EBITDA by segment: Three Months Ended March 31, (in thousands) 2017 2016 Adjusted EBITDA: Radiology $ 29,205 $ 26,443 Oncology 13,808 12,157 Interventional 1,055 1,255 Corporate / Other (11,310 ) (9,483 ) Total $ 32,758 $ 30,372
Reconciliation of Income Before Income Taxes, Earnings From Unconsolidated Investees, and Noncontrolling Interest to Total Adjusted EBITDA	The reconciliation of income before income taxes, earnings from unconsolidated investees, and noncontrolling interest to total Adjusted EBITDA is shown below: Three Months Ended March 31, (in thousands) 2017 2016 Income before income taxes, earnings from unconsolidated investees, and noncontrolling interest $ 4,122 $ 2,205 Earnings from unconsolidated investees 336 252 Interest expense, net 8,700 7,495 Depreciation expense 14,073 13,048 Amortization expense 3,275 2,443 Share-based payment (included in “ ” 381 1,865 Severance and related costs 634 1,716 Restructuring charges (Note 3) 215 231 Transaction costs 162 417 Shareholder transaction costs 869 1,009 Legal matters expense, net (included in “Selling, general and administrative expenses”) — 155 Changes in fair value of contingent consideration related to acquisitions (included in “Other income, net”) — (600 ) Other non-cash (benefits) charges, net (included in “Other income, net”) (9 ) 136 Total Adjusted EBITDA $ 32,758 $ 30,372
Summary of Identifiable Assets By Segment	The following table summarizes the Company’s identifiable assets by segment: March 31, December 31, (in thousands) 2017 2016 Identifiable assets: Radiology $ 290,480 $ 301,137 Oncology 251,382 256,456 Interventional 81,288 82,221 Corporate / Other 22,492 20,050 Total $ 645,642 $ 659,864
Summary of Capital Expenditures By Segment	The following table summarizes the Company’s equipment capital expenditures by segment: Three Months Ended March 31, (in thousands) 2017 2016 Capital expenditures: Radiology $ 812 $ 16,926 Oncology 12 484 Interventional 15 33 Corporate / Other — 232 Total $ 839 $ 17,675

Recent Accounting Pronounceme37

Recent Accounting Pronouncements - Additional Information (Details) $ in Millions	3 Months Ended
	Mar. 31, 2017USD ($)
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Tax deficiencies recognized on stock-based compensation expense	$ 0.2
Accounting Standards Update 2016-09
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Tax deficiencies recognized on stock-based compensation expense	$ 0.2

Transactions - Additional Infor

Transactions - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	Sep. 16, 2015	Mar. 31, 2017
Tahoe Oaktree M T S And Larry C Buckelew
Schedule of Business Acquisitions and Restructuring Transactions [Line Items]
Percentage of fees and expenses incurred by the Company in connection with the credit agreement that are attributable to Tahoe and Selling Stockholders	100.00%
Threshold above which reasonable and documented fees and expenses are attributable to Tahoe and Selling Stockholders	$ 1
Oaktree M T S And Larry C Buckelew
Schedule of Business Acquisitions and Restructuring Transactions [Line Items]
Capital contributions	15.3
Capital contributions, taxes	$ 0.2
Tahoe Investment Group Co Ltd
Schedule of Business Acquisitions and Restructuring Transactions [Line Items]
Number of shares acquired from Selling Stockholders	5,537,945
Consideration transferred	$ 102.5
Stock price per share	$ 18.50
Issuance of cash-based awards under management incentive agreement	$ 1.5
Capital contributions	$ 13.5
Ownership interest, percentage acquired		51.00%

Transactions - Restructuring Ch

Transactions - Restructuring Charges (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Restructuring Cost And Reserve [Line Items]
Restructuring charges	$ 215	$ 231
Cost of Revenues Excluding Depreciation and Amortization
Restructuring Cost And Reserve [Line Items]
Restructuring charges	77	200
Selling, General and Administrative Expenses
Restructuring Cost And Reserve [Line Items]
Restructuring charges	19	31
Other Expense, Net
Restructuring Cost And Reserve [Line Items]
Restructuring charges	$ 119	$ 0

Share-Based Payment - Additiona

Share-Based Payment - Additional Information (Details) - shares	Mar. 31, 2017	Nov. 30, 1999
Share Based Compensation [Abstract]
Common stock shares authorized for grant of options and awards (shares)		3,005,000
Common stock shares available for grant of options and awards (shares)	975,647

Share-Based Payment - Weighted

Share-Based Payment - Weighted Average Assumptions for Fair Value of Stock Options (Details)	3 Months Ended
	Mar. 31, 2016$ / shares
Weighted average assumptions for stock option awards
Risk free interest rate	1.53%
Expected dividend yield	0.00%
Expected stock price volatility	66.50%
Average expected life (in years)	6 years
Weighted average fair value on grant date	$ 7.16

Share-Based Payment - Stock Opt

Share-Based Payment - Stock Option Activity (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)$ / sharesshares
Number of Shares
Beginning balance | shares	650,969
Canceled/forfeited | shares	(26,242)
Ending balance | shares	624,727
Vested and expected to vest in the future | shares	598,945
Vested and exercisable | shares	500,086
Weighted Average Exercise Price
Beginning balance | $ / shares	$ 18.51
Canceled/forfeited | $ / shares	34.23
Ending balance | $ / shares	17.85
Vested and expected to vest in the future | $ / shares	18.31
Vested and exercisable | $ / shares	$ 20.51
Weighted Average Remaining Contractual Term
Ending balance	6 years 4 months 2 days
Vested and expected to vest in the future	6 years 2 months 19 days
Vested and exercisable	5 years 8 months 5 days
Aggregate Intrinsic Value
Outstanding | $	$ 1,119	[1]
Vested and expected to vest in the future | $	1,039	[1]
Vested and exercisable | $	$ 736	[1]
[1]	Represents the difference between the exercise price and the value of the Company’s stock at fiscal quarter-end.

Share-Based Payment - Unvested

Share-Based Payment - Unvested Stock Option Activity (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)$ / sharesshares
Shares
Beginning balance | shares	187,804
Vested | shares	(62,303)
Forfeited | shares	(860)
Ending balance | shares	124,641
Weighted Average Grant Date Fair Value
Beginning balance | $ / shares	$ 4.33
Vested | $ / shares	4.33
Forfeited | $ / shares	4.18
Ending balance | $ / shares	$ 4.33
Aggregate unrecognized compensation
Total Fair Value | $	$ 270
Stock Options
Aggregate unrecognized compensation
Aggregate unrecognized compensation | $	$ 421
Weighted average period over which expected to be recognized (in years)	2 years

Share-Based Payment - RSU Activ

Share-Based Payment - RSU Activity (Details) - Restricted stock units $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)$ / sharesshares
Rollforward of RSU activity - Shares
Beginning balance, unvested (shares) | shares	167,853
Vested (shares) | shares	(25,690)
Forfeited (shares) | shares	(519)
Ending balance, unvested (shares) | shares	141,644
Rollforward of RSU Activity - Weighted Average Grant Date Fair Value
Beginning balance, unvested, weighted-average grant-date fair value (dollars per share) | $ / shares	$ 8.37
Vested, weighted-average grant-date fair value (dollars per share) | $ / shares	6.93
Forfeited, weighted-average grant-date fair value (dollars per share) | $ / shares	6.93
Ending balance, unvested, weighted-average grant-date fair value (dollars per share) | $ / shares	$ 8.63
Aggregate unrecognized compensation
Aggregate unrecognized compensation | $	$ 929
Weighted average period over which expected to be recognized (in years)	1 year 1 month 6 days

Share-Based Payment - Summary o

Share-Based Payment - Summary of Pre-Tax Share-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Selling, General and Administrative Expenses
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 381	$ 1,865	[1]
[1]	Decrease in share-based compensation expense was primarily due to additional expense recognized during the three months ended March 31, 2016 related to a change in control in connection with the Tahoe Transaction in March 2016 (see Note 3). This includes cash paid of $463 related to market performance RSUs, granted to executive management, which vested upon a change in control of the Company under the terms of the RSU award agreement.

Share-Based Payment - Summary46

Share-Based Payment - Summary of Pre-Tax Share-Based Compensation Expense (Parenthetical) (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)
Share Based Compensation [Abstract]
Cash paid related to vested market performance RSUs	$ 463

Fair Value of Financial Instr47

Fair Value of Financial Instruments - Summary of Valuation of Financial Instruments Reported at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Financial liabilities:
Contingent consideration related to acquisitions	$ 535	$ 555
Mandatorily redeemable noncontrolling interest	2,386	2,386
Recurring basis
Financial assets:
Interest rate contracts - asset position	68	55
Total financial assets	68	55
Financial liabilities:
Contingent consideration related to acquisitions	535	555
Mandatorily redeemable noncontrolling interest	2,386	2,386
Interest rate contracts - liability position	26	53
Total financial liabilities	2,947	2,994
Recurring basis | Level 1
Financial assets:
Interest rate contracts - asset position	0	0
Total financial assets	0	0
Financial liabilities:
Contingent consideration related to acquisitions	0	0
Mandatorily redeemable noncontrolling interest	0	0
Interest rate contracts - liability position	0	0
Total financial liabilities	0	0
Recurring basis | Level 2
Financial assets:
Interest rate contracts - asset position	68	55
Total financial assets	68	55
Financial liabilities:
Contingent consideration related to acquisitions	0	0
Mandatorily redeemable noncontrolling interest	0	0
Interest rate contracts - liability position	26	53
Total financial liabilities	26	53
Recurring basis | Level 3
Financial assets:
Interest rate contracts - asset position	0	0
Total financial assets	0	0
Financial liabilities:
Contingent consideration related to acquisitions	535	555
Mandatorily redeemable noncontrolling interest	2,386	2,386
Interest rate contracts - liability position	0	0
Total financial liabilities	$ 2,921	$ 2,941

Fair Value of Financial Instr48

Fair Value of Financial Instruments - Schedule of Changes in Fair Value of Level 3 Liabilities (Details) - Level 3 $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)
Contingent Consideration Related to Acquisitions
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 555
Settlement	(20)
Ending balance	535
Mandatorily Redeemable Noncontrolling Interest
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balance	2,386
Settlement	0
Ending balance	$ 2,386

Fair Value of Financial Instr49

Fair Value of Financial Instruments - Summary of Financial Instruments Measured and Recorded at Fair Value on a Recurring Basis (Details) - Recurring basis - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Financial assets:
Other assets	$ 68	$ 55
Total financial assets	68	55
Financial liabilities:
Other accrued liabilities	2,947	2,994
Total financial liabilities	2,947	2,994
Level 1
Financial assets:
Other assets	0	0
Total financial assets	0	0
Financial liabilities:
Other accrued liabilities	0	0
Total financial liabilities	0	0
Level 2
Financial assets:
Other assets	68	55
Total financial assets	68	55
Financial liabilities:
Other accrued liabilities	26	53
Total financial liabilities	26	53
Level 3
Financial assets:
Other assets	0	0
Total financial assets	0	0
Financial liabilities:
Other accrued liabilities	2,921	2,941
Total financial liabilities	$ 2,921	$ 2,941

Fair Value of Financial Instr50

Fair Value of Financial Instruments - Additional Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)
Fair Value Disclosures [Abstract]
Transfers from one level to another	$ 0

Fair Value of Financial Instr51

Fair Value of Financial Instruments - Summary of Fair Values and Book Values of Long-term Debt (Details) - Level 2 - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Long-term debt, fair value	$ 565,064	$ 568,047
Long-term debt, book value	565,519	573,247
Variable-rate Debt
Debt Instrument [Line Items]
Long-term debt, fair value	526,447	526,475
Long-term debt, book value	528,879	533,939
Fixed-rate Debt
Debt Instrument [Line Items]
Long-term debt, fair value	38,617	41,572
Long-term debt, book value	$ 36,640	$ 39,308

Goodwill and Intangible Asset52

Goodwill and Intangible Assets - Changes in the Carrying Amount of Goodwill (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)
Goodwill [Line Items]
Beginning balance	$ 119,130
Goodwill acquired during the period	0
Adjustments to goodwill during the period	0
Ending balance	119,130
Gross goodwill	293,374
Accumulated impairment charges	(174,244)
Radiology
Goodwill [Line Items]
Beginning balance	45,157
Goodwill acquired during the period	0
Adjustments to goodwill during the period	0
Ending balance	45,157
Gross goodwill	199,499
Accumulated impairment charges	(154,342)
Oncology
Goodwill [Line Items]
Beginning balance	42,320
Goodwill acquired during the period	0
Adjustments to goodwill during the period	0
Ending balance	42,320
Gross goodwill	62,222
Accumulated impairment charges	(19,902)
Interventional
Goodwill [Line Items]
Beginning balance	31,653
Goodwill acquired during the period	0
Adjustments to goodwill during the period	0
Ending balance	31,653
Gross goodwill	31,653
Accumulated impairment charges	$ 0

Goodwill and Intangible Asset53

Goodwill and Intangible Assets - Components of Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Finite-lived intangible assets:
Weighted Average Useful Life (in years)	16 years
Gross Carrying Amount	$ 272,143	$ 272,143
Accumulated Amortization	(126,659)	(123,381)
Intangible Assets, Net	145,484	148,762
Indefinite-lived intangible assets	50,215	50,215
Total other intangible assets	$ 195,699	198,977
Customer contracts
Finite-lived intangible assets:
Weighted Average Useful Life (in years)	16 years
Gross Carrying Amount	$ 230,323	230,323
Accumulated Amortization	(104,179)	(101,240)
Intangible Assets, Net	$ 126,144	129,083
Other
Finite-lived intangible assets:
Weighted Average Useful Life (in years)	18 years
Gross Carrying Amount	$ 41,820	41,820
Accumulated Amortization	(22,480)	(22,141)
Intangible Assets, Net	$ 19,340	$ 19,679

Goodwill and Intangible Asset54

Goodwill and Intangible Assets - Estimated Future Amortization Expense (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Finite-lived intangible assets:
Remainder of 2017	$ 9,784
2,018	12,689
2,019	12,200
2,020	11,710
2,021	10,802
Thereafter	88,299
Intangible Assets, Net	$ 145,484	$ 148,762

Supplemental Balance Sheet In55

Supplemental Balance Sheet Information - Plant, Property and Equipment, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Property Plant And Equipment [Line Items]
Cost	$ 926,956	$ 939,810
Accumulated Depreciation	(732,622)	(734,996)
Net Carrying Amount	194,334	204,814
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Cost	4,835	4,905
Accumulated Depreciation	(4,202)	(4,231)
Net Carrying Amount	633	674
Office Equipment
Property Plant And Equipment [Line Items]
Cost	80,284	80,384
Accumulated Depreciation	(58,943)	(57,295)
Net Carrying Amount	21,341	23,089
Transportation and Service Equipment
Property Plant And Equipment [Line Items]
Cost	15,653	16,140
Accumulated Depreciation	(4,576)	(4,291)
Net Carrying Amount	11,077	11,849
Major Equipment
Property Plant And Equipment [Line Items]
Cost	783,155	794,153
Accumulated Depreciation	(635,361)	(639,452)
Net Carrying Amount	147,794	154,701
Tenant Improvements
Property Plant And Equipment [Line Items]
Cost	42,689	43,888
Accumulated Depreciation	(29,467)	(29,665)
Net Carrying Amount	13,222	14,223
Buildings and Land
Property Plant And Equipment [Line Items]
Cost	340	340
Accumulated Depreciation	(73)	(62)
Net Carrying Amount	$ 267	$ 278

Supplemental Balance Sheet In56

Supplemental Balance Sheet Information - Components of Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Components of other accrued liabilities
Systems rental and maintenance costs	$ 1,073	$ 1,064
Site rental fees	873	899
Property and sales taxes payable	7,537	7,254
Self-insurance accrual	2,705	2,612
Legal fees	1,921	1,537
Deferred gain on sale of equipment	87	87
Equipment purchases	446	848
Customer overpayments	2,149	2,555
Contingent consideration related to acquisitions	535	555
Mandatorily redeemable noncontrolling interest	2,386	2,386
Other accrued liabilities	7,944	9,526
Total	$ 27,656	$ 29,323

Long-Term Debt and Senior Sub57

Long-Term Debt and Senior Subordinated Credit Facility - Schedule of Long-term Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Deferred financing costs, net	$ (22,270)	$ (24,502)
Long-term debt, including current portion	543,249	548,745
Less current portion	(22,916)	(20,652)
Long-term debt	520,333	528,093
Term Loan Facility
Debt Instrument [Line Items]
Long-term debt, gross	496,374	497,674
Discount on term loan facility	(1,179)	(1,310)
Revolving Loan Facility
Debt Instrument [Line Items]
Long-term debt, gross	16,500	21,500
Equipment Under Capital Leases
Debt Instrument [Line Items]
Long-term debt, gross	15,217	16,040
Equipment Debt
Debt Instrument [Line Items]
Long-term debt, gross	$ 38,607	$ 39,343

Long-Term Debt and Senior Sub58

Long-Term Debt and Senior Subordinated Credit Facility - Additional Information (Details) - USD ($)	Mar. 29, 2016	Jun. 19, 2015	Jun. 03, 2013	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Oct. 11, 2013
Debt Instrument [Line Items]
Amount of financing fees paid				$ 223,000	$ 24,969,000
Debt instrument, interest rate terms				Borrowings under the Credit Agreement bear interest through maturity at a variable rate based upon, at the Company’s option, either the LIBOR or the base rate (which is the highest of the administrative agent’s prime rate, one-half of 1.00% in excess of the overnight federal funds rate, and 1.00% in excess of the one-month LIBOR rate), plus, in each case, an applicable margin.
Term Loan Facility
Debt Instrument [Line Items]
Long-term debt, gross				$ 496,374,000		$ 497,674,000
Revolving Loan Facility
Debt Instrument [Line Items]
Long-term debt, gross				$ 16,500,000		$ 21,500,000
Senior Notes
Debt Instrument [Line Items]
Stated percentage rate			8.00%
Senior Notes, face amount			$ 190,000,000
Minimum | Capital Leases
Debt Instrument [Line Items]
Stated percentage rate				2.68%
Maximum | Capital Leases
Debt Instrument [Line Items]
Stated percentage rate				6.23%
Equipment Debt | Bank Of The West
Debt Instrument [Line Items]
Financing agreement amendment execution date				Apr. 28, 2017
Equipment Debt | Minimum
Debt Instrument [Line Items]
Stated percentage rate				2.23%
Equipment Debt | Maximum
Debt Instrument [Line Items]
Stated percentage rate				9.00%
Credit Agreement
Debt Instrument [Line Items]
Quarterly amortization payments on term loan				$ 1,300,000
Ownership percentage of subsidiaries			50.00%
Covenant ratio of consolidated total debt to Consolidated Adjusted EBITDA				4.30%
Actual leverage ratio consolidated total debt to Consolidated Adjusted EBITDA				4.00%
Credit Agreement | Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate			1.00%
Debt description of variable rate basis				one-month LIBOR
Credit Agreement | Term Loan Facility
Debt Instrument [Line Items]
Credit facility borrowing capacity			$ 340,000,000
Debt term			6 years
Credit Agreement | Term Loan Facility | Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate			2.25%
Credit Agreement | Term Loan Facility | LIBOR
Debt Instrument [Line Items]
Basis spread on variable rate			3.25%
Credit Agreement | Revolving Loan Facility
Debt Instrument [Line Items]
Credit facility borrowing capacity			$ 50,000,000
Debt term			5 years
Credit facility, available borrowings				$ 29,200,000
Revolving credit facility				16,500,000
Credit Agreement | Letter of Credit
Debt Instrument [Line Items]
Credit facility borrowing capacity			$ 20,000,000
Long-term debt, gross				4,300,000
Credit Agreement | Uncommitted Incremental Loan Facility
Debt Instrument [Line Items]
Credit facility borrowing capacity			$ 100,000,000
Maximum debt leverage ratio allowed for additional incremental loan facilities			325.00%
Credit Agreement | Delayed Draw
Debt Instrument [Line Items]
Credit facility borrowing capacity			$ 80,000,000
Required draw period			30 days
Credit Agreement | Minimum
Debt Instrument [Line Items]
Covenant ratio of consolidated total debt to Consolidated Adjusted EBITDA			4.30%
Credit Agreement | Minimum | Term Loan Facility | LIBOR
Debt Instrument [Line Items]
LIBOR floor			1.00%
Credit Agreement | Minimum | Revolving Loan Facility
Debt Instrument [Line Items]
Commitment fee, percentage			0.38%
Credit Agreement | Minimum | Revolving Loan Facility | Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate			2.00%
Credit Agreement | Minimum | Revolving Loan Facility | LIBOR
Debt Instrument [Line Items]
Basis spread on variable rate			3.00%
LIBOR floor			1.00%
Credit Agreement | Maximum
Debt Instrument [Line Items]
Covenant ratio of consolidated total debt to Consolidated Adjusted EBITDA			4.95%
Credit Agreement | Maximum | Revolving Loan Facility
Debt Instrument [Line Items]
Commitment fee, percentage			0.50%
Credit Agreement | Maximum | Revolving Loan Facility | Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate			2.25%
Credit Agreement | Maximum | Revolving Loan Facility | LIBOR
Debt Instrument [Line Items]
Basis spread on variable rate			3.25%
First Amendment to New Credit Agreement | Committed Incremental Term Loan
Debt Instrument [Line Items]
Credit facility borrowing capacity							$ 70,000,000
Second Amendment To New Credit Agreement | Committed Incremental Term Loan
Debt Instrument [Line Items]
Credit facility borrowing capacity		$ 30,000,000
Principal amount funded (percent)		99.50%
Third Amendment to New Credit Agreement
Debt Instrument [Line Items]
Percentage of premium on prepayment of term loan	1.00%
Amount of financing fees paid	$ 24,969,000
Debt with PNC
Debt Instrument [Line Items]
Notes payable				7,800,000
Debt with PNC | Line of Credit [Member]
Debt Instrument [Line Items]
Credit facility borrowing capacity				3,000,000
Revolving credit facility				$ 500,000
Debt with PNC | Line of Credit [Member] | LIBOR
Debt Instrument [Line Items]
Basis spread on variable rate				1.50%
Debt with PNC | Minimum
Debt Instrument [Line Items]
Stated percentage rate				2.23%
Debt with PNC | Maximum
Debt Instrument [Line Items]
Stated percentage rate				2.29%

Derivatives - Additional Inform

Derivatives - Additional Information (Details) - Interest Rate Cash Flow Hedges - Variable-rate Debt - USD ($) $ in Millions	Mar. 31, 2017	Dec. 31, 2016
Derivative [Line Items]
Amount of hedged debt	$ 14.1	$ 15.5
Hedged debt as a percent of total debt (percent)	2.50%	2.70%

Derivatives - Summary of Intere

Derivatives - Summary of Interest Rate Cash Flow Hedges (Details) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2017	Dec. 31, 2016
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Derivative Liability, Notional Amount		$ 14,059
Fair Value Asset (Liability)	[1]	42	$ 2
Derivatives not designated hedging instruments | Interest Rate Swap
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Derivative Liability, Notional Amount		1,619
Fair Value Asset (Liability)	[1]		(2)
Fair Value Asset (Liability)	[1]	$ 2
Derivatives not designated hedging instruments | Interest Rate Swap | Minimum
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Derivative, Fixed Payment Rate		0.75%
Derivative, Maturity Date		Apr. 7, 2017
Derivatives not designated hedging instruments | Interest Rate Swap | Maximum
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Derivative, Fixed Payment Rate		1.68%
Derivative, Maturity Date		Apr. 23, 2020
Designated as Hedging Instrument | Interest Rate Swap Effective March2013
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Derivative Liability, Notional Amount		$ 952
Derivative, Fixed Payment Rate		2.87%
Derivative, Maturity Date		Apr. 1, 2018
Fair Value Asset (Liability)	[1]	$ 1	0
Designated as Hedging Instrument | Interest Rate Swap Effective December2012
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Derivative Liability, Notional Amount		$ 840
Derivative, Fixed Payment Rate		3.75%
Derivative, Maturity Date		Dec. 14, 2017
Fair Value Asset (Liability)	[1]	$ 0	(3)
Designated as Hedging Instrument | Interest Rate Swap Effective December2014
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Derivative Liability, Notional Amount		$ 917
Derivative, Fixed Payment Rate		1.34%
Derivative, Maturity Date		Nov. 30, 2019
Fair Value Asset (Liability)	[1]		(2)
Fair Value Asset (Liability)	[1]	$ 1
Designated as Hedging Instrument | Interest Rate Swap Effective December2015
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Derivative Liability, Notional Amount		$ 4,430
Derivative, Fixed Payment Rate		3.69%
Derivative, Maturity Date		Dec. 1, 2021
Fair Value Asset (Liability)	[1]	$ (8)	(24)
Designated as Hedging Instrument | Interest Rate Swap Two Effective December2015
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Derivative Liability, Notional Amount		$ 1,096
Derivative, Fixed Payment Rate		1.37%
Derivative, Maturity Date		Dec. 15, 2020
Fair Value Asset (Liability)	[1]	$ 3	0
Designated as Hedging Instrument | Interest Rate Swap Effective September2016
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Derivative Liability, Notional Amount		$ 4,205
Derivative, Fixed Payment Rate		1.17%
Derivative, Maturity Date		Sep. 30, 2021
Fair Value Asset (Liability)	[1]	$ 43	$ 33
[1]	The fair values of the interest rate swap asset and liabilities are included in “Other assets” and “Other accrued liabilities,” respectively, in the condensed consolidated balance sheets.

Derivatives - Summary of Inte61

Derivatives - Summary of Interest Rate Cash Flow Hedges (Parenthetical) (Details) - Designated as Hedging Instrument - LIBOR	Mar. 31, 2017
Interest Rate Swap Effective December2012
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Interest rate agreement, basis spread on variable rate (percent)	2.50%
Interest Rate Swap Effective March2013
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Interest rate agreement, basis spread on variable rate (percent)	2.00%
Interest Rate Swap One Effective December2015
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Interest rate agreement, basis spread on variable rate (percent)	2.00%

Derivatives - Impact on Stateme

Derivatives - Impact on Statements of Operations and Comprehensive Loss (Details) - Designated as Hedging Instrument - Derivatives in Cash Flow Hedging Relationships - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Recognized in OCI on Derivatives (Effective Portion)	$ 13	$ (79)
Amount of Loss (Gain) Reclassified from Accumulated OCI into Income (Effective Portion)	19	(83)
Amount of Gain (Loss) Recognized in Income on Derivatives Income (Ineffective Portion)	0	0
Interest rate contracts
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Recognized in OCI on Derivatives (Effective Portion)	13	(79)
Interest rate contracts | Interest expense, net
Derivative Instruments Gain Loss [Line Items]
Amount of Loss (Gain) Reclassified from Accumulated OCI into Income (Effective Portion)	19	(83)
Amount of Gain (Loss) Recognized in Income on Derivatives Income (Ineffective Portion)	$ 0	$ 0

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income tax benefit	$ 3	$ 945
Income tax benefit as a percentage of pre-tax loss		44.30%
Tax deficiencies recognized on stock-based compensation expense	200
Unrecognized tax benefits related to various federal and state income tax matters	300		$ 300
Tax-effected amount that would reduce the Company's effective income tax rate if recognized	$ 200		$ 200

Loss Per Common Share (Details)

Loss Per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Numerator:
Net loss attributable to Alliance HealthCare Services, Inc.	$ (614)	$ (1,190)
Denominator:
Weighted average shares — basic (shares)	10,973	10,779
Effect of dilutive securities:
Stock options and RSUs	0	0
Weighted average shares — diluted (shares)	10,973	10,779
Net loss per common share attributable to Alliance HealthCare Services, Inc.:
Basic	$ (0.06)	$ (0.11)
Diluted	$ (0.06)	$ (0.11)
Stock options excluded from the computation of diluted per share amounts:
Weighted average shares for which the exercise price exceeds average market price of common stock	323	465
Average exercise price per share that exceeds average market price of common stock (dollars per share)	$ 29.37	$ 25.34

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Commitments and Contingencies [Line Items]
Maintenance contracts with equipment vendors, expiration year	2,021
Equipment maintenance contract payments	$ 11,100,000	$ 10,300,000
Liability related to guarantees and indemnities	$ 0
Minimum
Commitments and Contingencies [Line Items]
Period since inception of equipment maintenance contract	1 year
Maximum
Commitments and Contingencies [Line Items]
Period since inception of equipment maintenance contract	5 years
Equipment Purchase Commitments
Commitments and Contingencies [Line Items]
Equipment purchase commitment	$ 15,200,000

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details)	Mar. 31, 2017unconsolidated_investee	Dec. 31, 2016unconsolidated_investee	Sep. 16, 2015shares
Related Party Transaction [Line Items]
Number of unconsolidated entities with direct ownership (investee) | unconsolidated_investee	2	2
Tahoe Investment Group Co Ltd
Related Party Transaction [Line Items]
Number of shares acquired | shares			5,537,945
Ownership interest, percentage acquired	51.00%

Related Party Transactions - Su

Related Party Transactions - Summary of Revenue and Reimbursed Expenses with Unconsolidated Equity Investees (Details) - Equity Method Investee - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Related Party Transaction [Line Items]
Revenue from management agreements	$ 474	$ 353
Revenue and reimbursed expenses	$ 363	$ 252

Investments in Unconsolidated68

Investments in Unconsolidated Investees - Additional Information (Details) - unconsolidated_investee	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Schedule Of Equity Method Investments [Line Items]
Number of unconsolidated entities with direct ownership (investee)	2	2
Maximum
Schedule Of Equity Method Investments [Line Items]
Management services agreements' expiration period	2,025
Unconsolidated Subsidiary One
Schedule Of Equity Method Investments [Line Items]
Percentage of ownership of investee (percent)	15.00%
Unconsolidated Subsidiary Two
Schedule Of Equity Method Investments [Line Items]
Percentage of ownership of investee (percent)	50.00%

Investments in Unconsolidated69

Investments in Unconsolidated Investees - Balance Sheet Data and Operating Results (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Balance sheet data:
Current assets	$ 3,841		$ 2,860
Noncurrent assets	84		111
Current liabilities	660		760
Noncurrent liabilities	31		$ 32
Operating results:
Revenues	2,593	$ 2,301
Expenses	790	778
Net income	1,803	1,523
Earnings from unconsolidated investees	$ 336	$ 252

Stockholders' Deficit (Details)

Stockholders' Deficit (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Class Of Stock [Line Items]
Beginning balance	$ (9,503)	$ (77,620)
Exercise of stock options		486
Shareholder transaction		28,629
Share-based payment	381	1,402
Share-based payment income tax benefit		345
Other comprehensive income (loss)	32	(38)
Distributions to noncontrolling interest in subsidiaries	(5,600)	(2,433)
Contributions from noncontrolling interest in subsidiaries	286
Net (loss) income	4,461	3,402
Ending balance	(9,943)	(45,827)
Treasury Stock
Class Of Stock [Line Items]
Beginning balance	$ (3,138)	$ (3,138)
Beginning balance, shares	(157,973)	(157,973)
Ending balance	$ (3,138)	$ (3,138)
Ending balance, shares	(157,973)	(157,973)
Additional Paid-In Capital
Class Of Stock [Line Items]
Beginning balance	$ 61,353	$ 29,297
Exercise of stock options		485
Shareholder transaction		28,629
Share-based payment	381	1,402
Share-based payment income tax benefit		345
Ending balance	61,734	60,158
Accumulated Comprehensive Income
Class Of Stock [Line Items]
Beginning balance	10	(511)
Other comprehensive income (loss)	32	(38)
Ending balance	42	(549)
Accumulated Deficit
Class Of Stock [Line Items]
Beginning balance	(197,900)	(198,393)
Net (loss) income	(614)	(1,190)
Ending balance	(198,514)	(199,583)
Alliance HealthCare Services, Inc.
Class Of Stock [Line Items]
Beginning balance	(139,565)	(172,637)
Exercise of stock options		486
Shareholder transaction		28,629
Share-based payment	381	1,402
Share-based payment income tax benefit		345
Other comprehensive income (loss)	32	(38)
Net (loss) income	(614)	(1,190)
Ending balance	(139,766)	(143,003)
Noncontrolling Interest
Class Of Stock [Line Items]
Beginning balance	130,062	95,017
Distributions to noncontrolling interest in subsidiaries	(5,600)	(2,433)
Contributions from noncontrolling interest in subsidiaries	286
Net (loss) income	5,075	4,592
Ending balance	129,823	97,176
Common Stock
Class Of Stock [Line Items]
Beginning balance	$ 110	$ 108
Beginning balance, shares	10,970,937	10,774,857
Vesting of stock awards, net	18,336
Exercise of stock options		$ 1
Exercise of stock options, shares		100,000
Ending balance	$ 110	$ 109
Ending balance, shares	10,989,273	10,874,857

Segment Information - Additiona

Segment Information - Additional Information (Details)	3 Months Ended
	Mar. 31, 2017segment
Segment Reporting [Abstract]
Number of operating segments (segment)	3
Reconciliation of operating profit (loss) from segments to consolidated	Adjusted EBITDA represents net income before: income taxes; net income attributable to noncontrolling interest; interest expense, net; depreciation expense; amortization expense; share-based payment; severance and related costs; restructuring charges; transaction costs; shareholder transaction costs; legal matters expense, net; changes in fair value of contingent consideration related to acquisitions; and other non-cash (benefits) charges, net. Adjusted EBITDA is the most frequently used measure of each segment’s performance and is commonly used in setting performance goals.

Segment Information - Revenue b

Segment Information - Revenue by Segment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Summary of revenue by segment
Revenue	$ 129,936	$ 123,725
Operating Segments | Radiology
Summary of revenue by segment
Revenue	87,812	85,639
Operating Segments | Oncology
Summary of revenue by segment
Revenue	30,033	26,062
Operating Segments | Interventional
Summary of revenue by segment
Revenue	11,652	11,663
Operating Segments | MRI | Radiology
Summary of revenue by segment
Revenue	49,455	47,570
Operating Segments | PET/CT | Radiology
Summary of revenue by segment
Revenue	32,180	31,666
Operating Segments | Other Radiology | Radiology
Summary of revenue by segment
Revenue	6,177	6,403
Corporate / Other
Summary of revenue by segment
Revenue	$ 439	$ 361

Segment Information - Summary o

Segment Information - Summary of Adjusted EBITDA by Segment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Summary of Adjusted EBITDA:
Adjusted EBITDA	$ 32,758	$ 30,372
Segment Continuing Operations
Summary of Adjusted EBITDA:
Adjusted EBITDA	32,758	30,372
Segment Continuing Operations | Operating Segments | Radiology
Summary of Adjusted EBITDA:
Adjusted EBITDA	29,205	26,443
Segment Continuing Operations | Operating Segments | Oncology
Summary of Adjusted EBITDA:
Adjusted EBITDA	13,808	12,157
Segment Continuing Operations | Operating Segments | Interventional
Summary of Adjusted EBITDA:
Adjusted EBITDA	1,055	1,255
Segment Continuing Operations | Corporate / Other
Summary of Adjusted EBITDA:
Adjusted EBITDA	$ (11,310)	$ (9,483)

Segment Information - Reconcili

Segment Information - Reconciliation of Income Before Income Taxes, Earnings from Unconsolidated Investees, and Noncontrolling Interest to Total Adjusted EBITDA (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Reconciliation of net (loss) income to total Adjusted EBITDA
Income before income taxes, earnings from unconsolidated investees, and noncontrolling interest	$ 4,122	$ 2,205
Earnings from unconsolidated investees	336	252
Interest expense, net	8,700	7,495
Depreciation expense	14,073	13,048
Severance and related costs	634	1,716
Restructuring charges	215	231
Transaction costs	162	417
Shareholder transaction costs	869	1,009
Total Adjusted EBITDA	32,758	30,372
Segment Reconciling Items
Reconciliation of net (loss) income to total Adjusted EBITDA
Earnings from unconsolidated investees	336	252
Interest expense, net	8,700	7,495
Depreciation expense	14,073	13,048
Amortization expense	3,275	2,443
Share-based payment (included in “Selling, general and administrative expenses”)	381	1,865
Severance and related costs	634	1,716
Restructuring charges	215	231
Transaction costs	162	417
Shareholder transaction costs	869	1,009
Legal matters expense, net (included in “Selling, general and administrative expenses”)	0	155
Changes in fair value of contingent consideration related to acquisitions (included in “Other income, net”)	0	(600)
Other non-cash (benefits) charges, net (included in “Other income, net”)	$ (9)	$ 136

Segment Information - Summary75

Segment Information - Summary of Identifiable Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Summary of Company's identifiable assets by segment
Identifiable assets	$ 645,642	$ 659,864
Operating Segments | Radiology
Summary of Company's identifiable assets by segment
Identifiable assets	290,480	301,137
Operating Segments | Oncology
Summary of Company's identifiable assets by segment
Identifiable assets	251,382	256,456
Operating Segments | Interventional
Summary of Company's identifiable assets by segment
Identifiable assets	81,288	82,221
Corporate / Other
Summary of Company's identifiable assets by segment
Identifiable assets	$ 22,492	$ 20,050

Segment Information - Summary76

Segment Information - Summary of Capital Expenditures (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Summary of Company's capital expenditures by segment
Capital expenditures	$ 839	$ 17,675
Operating Segments | Radiology
Summary of Company's capital expenditures by segment
Capital expenditures	812	16,926
Operating Segments | Oncology
Summary of Company's capital expenditures by segment
Capital expenditures	12	484
Operating Segments | Interventional
Summary of Company's capital expenditures by segment
Capital expenditures	15	33
Corporate / Other
Summary of Company's capital expenditures by segment
Capital expenditures	$ 0	$ 232

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - Subsequent Event $ / shares in Units, $ in Millions	Apr. 10, 2017USD ($)$ / shares
Subsequent Event [Line Items]
Subsequent Event, description	As discussed in Note 1, on April 10, 2017, the Company entered into a Merger Agreement with the Purchaser Parties, pursuant to which Tahoe will acquire all of the Company’s outstanding common stock that is not beneficially owned by Tahoe or owned by the Company as treasury shares, for $13.25 per share.
Subsequent Event, date	Apr. 10, 2017
Merger agreement, termination date	Dec. 15, 2017
Merger agreement, term of extension beyond termination date	60 days
Company Change in Recommendation of Merger
Subsequent Event [Line Items]
Gain (loss) on contract termination	$ (1.5)
Certain Circumstances
Subsequent Event [Line Items]
Gain (loss) on contract termination	$ 4.5
Tahoe Investment Group Co Ltd
Subsequent Event [Line Items]
Proposed purchase price | $ / shares	$ 13.25